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ABSTRACT 
 
The main aim of this study is the development of two controlled drug delivery systems based on 
ordered mesoporous silica and erythrocyte membranes (in further text - ghosts) for two widely 
used drugs: fenofibrate and sodium diclofenac. 
In the first part of the study, in vitro and in vivo performance of ordered mesoporous silica (OMS) 
as a carrier for the poorly water soluble compound fenofibrate was evaluated. Fenofibrate was 
loaded into OMS via incipient wetness impregnation to obtain a 29% drug load and formulated 
into capsules. Two capsule dosage forms (containing 33.5 mg and 16.75 mg fenofibrate) were 
compared to the commercially available forms - Lipanthyl® (fenofibrate microcrystals) and 
Tricor® (fenofibrate nanocrystals). In vitro dissolution tests showed that the amount of fenofibrate 
released from Lipanthyl® and Tricor® was approximately 30%, whereas ca. 66 and 60% of the 
drug was released from OMS capsules containing 33.5 and 16.75 mg of fenofibrate, respectively. 
The in vivo study in dogs confirmed satisfying level of safety and tolerability of fenofibrate-OMS 
formulation (eq. 33.5 mg) with the potential to improve the absorption of fenofibrate. Though 
some variability in the data, this formulation was promising to be further investigated in a clinical 
trial setting. Subsequent clinical trial was conducted to assess the bioavailability-enhancing 
potential of ordered mesoporous silica in man. In this open-label, randomized, two-way cross-over 
study, 12 overnight fasted healthy volunteers received a single dose of fenofibrate formulated with 
ordered mesoporous silica or a marketed product based on micronized fenofibrate. Plasma 
concentrations of fenofibric acid, the pharmacologically active metabolite of fenofibrate, were 
monitored up to 96 hours post-dose. The rate (Cmax/dose increased by 77%; tmax reduced by 0.75 
h) and extent of absorption (AUC0-24h/dose increased by 54%) of fenofibrate were significantly 
enhanced following administration of the ordered mesoporous silica based formulation.  
In the second part of the study controlled drug delivery system based on erythrocyte ghosts for 
amphiphilic compound sodium diclofenac was developed considering the differences between 
erythrocytes derived from two readily available materials - porcine slaughterhouse and outdated 
transfusion human blood. Starting erythrocytes, empty erythrocyte ghosts and diclofenac loaded 
ghosts were compared in terms of the encapsulation efficiency, drug releasing profiles, size 
distribution, surface charge, conductivity, surface roughness and morphology. The encapsulation 
of sodium diclofenac was performed by an osmosis based process - gradual hemolysis. During this 
process sodium diclofenac exerted mild and delayed antihemolytic effect and increased potassium 
efflux in porcine but not in outdated human erythrocytes. FTIR spectra revealed lack of any 
membrane lipid disorder and chemical reaction with sodium diclofenac in encapsulated ghosts. 
Localization in the suspension and spatial distribution (i. e. mapping) of residual hemoglobin in 
erythrocyte ghosts has been resolved by two photon excitation fluorescence microscopy. Outdated 
human erythrocyte ghosts with detected nanoscale damages and reduced ability to shrink had 
encapsulation efficiency of only 8%. On the other hand, porcine erythrocyte ghosts had 
encapsulation efficiency of 37% and relatively slow drug release rate. More preserved structure 
and functional properties of porcine erythrocytes related to their superior encapsulation and release 
performances, define them as more appropriate for the usage in sodium diclofenac encapsulation 
process. 
 
Key words: Ordered mesoporous silica, fenofibrate, poor solubility, oral bioavailability, 
erythrocyte membranes; encapsulation; sodium diclofenac, gradual hypotonic hemolysis, 
controlled drug delivery. 
Scientific filed: Technological engineering 
Scientific discipline: Biochemical engineering and Biotechnology 
UDC number: 
 
 
 
 
 
 
IZVOD 
Glavni cilj ovog rada je razvoj dva sistema sa kontrolisanim otpuštanjem lekova zasnovanih na 
uređenoj mezoporoznoj silici i eritrocitnim membranama (u daljem tekstu duhovima) za dva leka 
u širokoj upotrebi: fenofibrat i natrijum diklofenak. 
U prvom delu ove studije ispitivane su in vitro i in vivo performase uređene mezoporozne silike 
kao nosača za slabo rastvorni lek fenofibrat. Mezoporozna silika je punjena fenofibratom metodom 
vlažne impregnacije incipijenta dok sadržaj leka ne dostigne 29%, a potom finalno formulisana 
kao kapusla. Dve vrste kapsula (koje sadrže 33.5 mg i 16.75 mg fenofibrata) poređene su sa 
komercijalno dostupnim oblicima - Lipantil® (fenofibrat mikrokristali) i Trikor® (fenofibrat 
nanokristali). In vitro testovi rastvorljivosti pokazali su da je količina fenofibrata oslobođenog iz 
Lipantila® i Trikora® aproksimativno iznosila 30% dok je oko 66 i 60% leka oslobođeno iz 
kapsula sa mezoporoznom silikom koje su sadržale 33.5 i 16.75 mg fenofibrata, respektivno. In 
vivo studija na psima potvrdila je zadovoljavajući nivo bezbednosti i tolerantnosti formulacija sa 
mezoporoznom silikom i fenofibratom (33.5 mg) kao i potencijal za poboljšanje apsorpcije 
fenofibrata. Uprkos variabilnosti dobijenih podataka, ova formulacija je bila obećavajuća za 
buduća klinička ispitivanja. Sledstvena klinička studija izvedena je sa ciljem da se proceni 
potencijal uređene mezoporozne silike da poboljša bioraspoloživost fenofibrata kod čoveka. U 
ovoj otvorenoj, randomizovanoj, dvostruko ukrštenoj studiji, 12 zdravih volontera je primilo 
pojedinačnu dozu fenofibrata formulisanog sa uređenom mezoporoznom silikom kao i 
komercijalni proizvod baziran na mikroniziranom fenofibratu. Plazma koncentracije fenofibrinske 
kiseline, farmakološki aktivnog metabolita fenofibrata bile su praćene 96 sati nakon uzete doze. 
Stepen (odnos Cmax/doza bio je povećan 77%, a tmax redukovano za 0,75 h) i obim apsorpcije (PIK0-
24 h je bila uvećana za 54%) fenofibrata su bili značajno povećani nakon administracije formulacije 
zasnovane na uređenoj mezoporoznoj silici. 
U drugom delu studije razvijen je sistem sa kontrolisanim otpuštanjem za amfifilni lek natrijum 
diklofenak uz razmatranje razlika između eritrocita izolovanih iz dva lako dostupna materijala – 
svinjske otpadne klanične i prestarele humane krvi. Polazni eritrociti, prazni eritrocitni duhovi kao 
i inkapsulirani duhovi bili su poređeni u smislu efikasnosti inkapsulacije, profila oslobađanja leka, 
raspodele veličine, površinskog naelektrisanja, provodljivosti, hrapavosti površine i morfologije. 
Inkapsulacija natrijum diklofena izvedena je procesom zasnovanim na osmozi – gradualnom 
hemolizom. Tokom ovog procesa natrijum diklofenak ispoljio je blag i odložen antihemolitički 
efekat kao i povećan efluks kalijuma kod svinjskih ali ne i kod prestarelih humanih eritrocita. FTIR 
spektri su otkrili odsustvo narušavanja strukture membranskih lipida kao i hemijske reakcije 
između natrijum diklofena i inkapsuliranih duhova. Lokalizacija rezidualnog hemoglobina u 
suspenziji eritrocitinih duhova i njegova prostorna distribucija određeni su primenom dvofotonske 
fluorescentne mikroskopije. Prestareli humani eritrocitni duhovi sa detektovanim oštećenjma na 
površini i smanjenom sposobnošću da se skupljaju imali su efikasnost inkapsulacije od samo 8%. 
Sa druge strane, svinjski eritrocitni duhovi su imali efikasnost inkapsulacije od 37% i relativno 
nisku brzinu oslobađanja leka. Viši stepen očuvanosti strukture i funkcije svinjskih eritrocita 
posmatran kroz superiornije performanse inkapsulacije i oslobađanja leka, definiše ih kao 
pogodniji materijal za inkapsulaciju natrijum diklofena. 
 
Ključne reči: uređena mezoporozna silika, fenofibrat, slaba ratvorljivost, oralna bioraspoloživost, 
eritrocitne membrane, inkapsulacija, gradualna hipotonična hemoliza, sistemi sa kontrolisanim 
otpuštanjem. 
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INTRODUCTION 
 
 
Solubility, the phenomenon of dissolution of solute in solvent in order to obtain homogenous 
system, is very important parameter to achieve required concentration of the drug in systemic 
circulation for expected pharmacological response (Ketan et al., 2010). Nowadays when more 
than 40% of new chemical entities developed in pharmaceutical industry are practically insoluble 
in water the problem of solubility represent a major challenge for formulation scientist (Sharma 
et al., 2009). 
Other important issues encountered by pharmaceutical scientists during the drug development 
are adverse effects of drugs. It is well known that pharmaceutical agents are one of the most 
commonly identified causes of adverse events, resulting in significant patient morbidity, 
mortality and excess medical care costs (Phillips et al., 2001). One extensive study estimated 
that more than 2 million hospitalized patients have severe adverse drug reactions annually in the 
United States even in the case of correct prescription and administration (Phillips et al., 2001). 
Also, adverse effects are ranked between the fourth and the sixth leading cause of death in the 
United States in 1994 (Phillips et al., 2001). 
Since poor water-solubility of the drugs as well as their frequent adverse effects represent main 
problems in their development, there is a necessity for the controlled drug delivery systems 
which will allow better control of the drug level in plasma, less dosing frequency, decrease in 
adverse effects, improved efficiency and constant release. Two widely used drugs - fenofibrate 
and diclofenac sodium which are due to their efficacy first choice medications for the indicated 
pathological states, were chosen as model compounds. 
Fenofibrate is a highly lipophilic drug used to normalize the plasma titer of low-density 
lipoproteins and cholesterol in patients with hypercholesterolemia and hypertriglyceridemia 
(Guay et al., 1993, Genest et al., 2000). As a typical Biopharmaceutical Classification System 
(BCS) class 2 compound (log P = 5.24), it is virtually insoluble in water and physiological fluids 
(Ming-Thau et al., 1994). Its insufficient absorption from the aqueous environment of the 
gastrointestinal tract results in very low systemic exposure after oral administration (Guay et al., 
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1993). Thus, oral bioavailability of fenofibrate may be improved by increasing its aqueous 
solubility (Yousaf et al. 2015). Even though over the past few years, several conventional 
formulation techniques, such as micro- and nanonization (Hens et al., 2015), formation of 
liposomes (Chen et al., 2009), various polymeric nanoparticulated systems (Yousaf et al., 2015) 
and lipid based formulations (Fei et al., 2013) have been employed to enhance the oral 
bioavailability of fenofibrate, the number of marketed applications of these technologies remains 
very limited. 
Ordered mesoporous silica (OMS) is a promising strategy to increase the apparent aqueous 
solubility and dissolution rate of poorly water-soluble entities (Xu et al., 2013). Mellaerts et al. 
were the first to correlate the increased release rate of itraconazole from OMS with an increase in 
bioavailability and demonstrated a performance comparable to that of the marketed product 
sporanox (Mellaerts et al., 2008). OMS with a pore size ranging from 4 to 10 nm in diameter, 
large specific pore volume (ca. 1 cm3/g) and surface area (ca. 1000 m2/g) (Vialpando et al., 
2012) provides high drug load and increase in dissolution rate of active pharmaceutical 
ingredients (API) to the highest possible level (Van Speybroeck et al., 2009). The principle of 
the dissolution improvement is based on the adsorption of an API onto the surface of the carrier 
material in a molecular manner (Mellaerts et al., 2007). Since the deposition of an API in the 
mesopores of the carrier is associated with the suppression of crystallization of the entrapped 
molecules, mesoporous silica materials are excellent stabilizers for amorphous APIs (Van 
Speybroeck et al., 2009). When exposed to water, the adsorbed drug molecules compete for the 
hydrophilic silica surface and are released from the pores. Consequently, in this "dissolved" state 
they become available for absorption in the gastrointestinal tract (Kiekens et al., 2011). 
The ability of mesoporous silica to improve the dissolution profile of fenofibrate in biorelevant 
media has already been described in literature (Dressman et al., 2015; Fei et al., 2013; Van 
Speybroeck., 2010). However, in this study, for the first time, the biopharmaceutical 
performance of OMS based formulations was determined in dogs by comparing the oral 
bioavailability of fenofibrate loaded onto OMS material with two marketed formulations 
Lipanthyl® (microcrystals of fenofibrate) and Tricor® (nanocrystals of fenofibrate). The results 
indicate that OMS could be a potential carrier to achieve enhanced oral bioavailability for 
fenofibrate. Moreover, it provides valuable information about formulation selection to be used 
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for further in vivo testing, in humans. Subsequent clinical trial was set up to complement these 
promising findings with in vivo data in man. To the best of our knowledge, no prior papers have 
reported on the oral administration of ordered mesoporous silica based formulations in man. 
Sodium diclofenac (SD) is a potent non-steroidal anti-inflammatory drug with analgesic and 
antipyretic effects. However, due to its physicochemical action on the gastric mucous (Odsson et 
al., 1990) and inflammatory action on the small bowel and the colon (Carson et al., 1990; 
Witham, 1991), it counts for a risk factor of relatively high incidence of gastrointestinal side 
effects. Because of the mentioned side effects and its short biological half-life (Todd et al., 
1988), SD is an ideal candidate for prolonged release preparations with the aim to maintain 
therapeutic activity, reduce toxic effects and improve patient compliance (Krajisnik et al., 2013). 
Many chemically- synthetized or naturally occurring carrier materials such as phospholipid 
liposomes (Lopes et al., 2004), sodium alginate beads (Kulkarni et al., 1999), PLGA-based 
nanoparticles (Cooper et al., 2014), silica-chitosan composites (Kozakevych et al., 2013), solid 
lipid nanoparticles (Liu et al., 2014) have been employed to design micro- or nano- sized 
prolonged/controlled delivery systems for SD. However, in general, the surface chemistry of the 
mentioned carriers differs substantially from the chemistry of the cell membrane (Mao et al., 
2011). Studies conducted on liposomes showed that SD due to its surface-active properties can 
incorporate into membranes affecting the lipidic organization and leading to solubilisation of the 
structure (Lopes et al., 2004). On the other hand, erythrocyte membrane, which is more complex 
than liposomal membrane and also interact with SD via class of lipids found in its outer moiety 
(Suwalsky et al., 2009), but without the disruption, might be a naturally occurring alternative 
offering potential advantage in comparison with the liposomes as drug carriers. However, to the 
best authors' knowledge, literature data regarding erythrocyte based delivery systems for SD is 
very scarce and there hasn’t been any attempt since Jain et al. (1994) developed magnetically 
responsive SD loaded erythrocytes (Jain et al., 1994).  
The majority of research groups are dealing with active substances encapsulation in small 
amount of autologous erythrocytes intended for personal medicine. Having in mind the ultimate 
goal of universal erythrocyte membrane based SD carrier production, the use of non-infectious 
blood material generally treated as waste, such are slaughterhouse blood and outdate transfusion 
human blood represent beneficial approach in the development of an added-value product. This 
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approach is supported by the increasing number of emerging techniques for covering antigenic 
determinants (Mansouri et al., 2011), which could allow application of these materials as 
carriers and the fact that these materials are available in unlimited amounts. Thus, we have 
recently shown that osmosis based process - gradual hemolysis can be used for loading 
dexamethasone sodium phosphate on large scale into erythrocytes’ ghosts derived from porcine 
and bovine slaughterhouse blood (Kostic et al., 2014).  
In xenotransplantation research, a pig accounts for the favoured available source of organs and 
tissues (Doucet et al., 2004). Therefore, in this study we examined the gradual hypotonic 
hemolysis as an osmosis based SD encapsulation process in erythrocyte membranes derived from 
two inexpensive, available in sufficient amount materials - porcine slaughterhouse and outdated 
human blood. Obtained formulations with encapsulated SD were characterized in terms of 
encapsulation efficiency, drug release profile, morphology, size and surface properties. 
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THEORETICAL PART 
 
1. Controlled drug delivery systems 
1.1. The definition and history of the development of controlled 
drug delivery systems 
 
According to the definition, controlled release system represents any drug delivery system that 
maintains adequate and desired release of drug over an extended period of time (Kushal et al., 
2013). The main aim of an ideal drug delivery system is to provide proper amount of the drug at 
regular time interval and at right site of action to maintain required therapeutic range in the blood 
(Kushal et al., 2013). The goal in the development of the controlled release drug delivery system 
is to decrease the frequency of the dosing, reducing the dose and provide uniform drug delivery 
(Kushal et al., 2013). So, controlled release dosage form is a dosage form that releases one or 
more drugs continuously in predetermined pattern for a fixed period of time, either systemically 
or locally to specified target organ (John, 2002; Brahmankar, 2009; Lee, 1987). The benefits of 
the controlled release dosage forms include better control of plasma drug levels, less dosage 
frequency, less side effects, increased efficacy and constant delivery (Kushal et al., 2013). 
Before 1950 all drugs were formulated as a pill or capsule that released the loaded drug 
immediately after the contact with water without any ability to control the drug release kinetics 
(Yun et al., 2015). The first sustained release formulation developed by Smith Klein Beecham 
named Spansule technology, that was able to control the drug release kinetics and achieve 12-h 
efficacy was introduced in 1952. (Lee, 1987).  
The historical overview of controlled drug delivery systems is represented in Table 1. Most of 
the fundamental understanding of the drug releasing mechanism, especially oral and transdermal 
dosage forms, was obtained during the first generation (1G) of the development from 1950 to 
1980 (Yun et al., 2015). During this period, four releasing mechanisms were revealed which 
accelerated the development of numerous oral and transdermal controlled release formulations 
(Yun et al., 2015). The most frequently used mechanisms were dissolution-controlled and 
diffusion-controlled systems. Osmosis-based formulations had short-term popularity, but a 
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number of products based on osmosis is much smaller than those with the other two (Yun et al., 
2015). The ion-exchange mechanism has not been useful without combining with diffusion-
controlled mechanism (Yun et al., 2015). 
Different from 1G drug delivery formulations, the second generation (2G) technologies have 
been less successful, taking into account the number of clinical products produced (Yun et al., 
2015). The drug delivery systems developed during the 2G period faced more difficult issues in 
comparison with the 1G technologies (Yun et al., 2015). The technologies developed during the 
2 G period are presented in Table 1.  
 
Table 1. Historical overview of drug delivery technology from 1950 to the present and the 
technology necessary for the future (Yun et al., 2015). 
         1950                                      1980                                         2010                                    2040 
1st Generation 2nd Generation 3rd Generation 
Basics of controlled release Smart delivery systems Modulated delivery systems 
Oral delivery: 
-Once a day, twice a day 
Zero order release 
-First order vs Zero order 
Poorly soluble drug delivery 
-Non-toxic excipients 
Transdermal delivery: 
-Once a day, once a week 
Peptide and protein delivery: 
-Long-term depot using 
biodegradable polymers 
-Pulmonary delivery 
Peptide and protein delivery: 
-Delivery for >6 months 
-Control of release kinetics 
-Non-invasive delivery 
Drug release mechanisms: 
-Dissolution 
-Diffusion 
-Osmosis 
-Ion-exchange 
 
Smart polymers and hydrogels: 
-Environment-sensitive 
-Self-regulated release 
(working only in vitro) 
Smart polymers and hydrogels: 
-Signal specificity and sensitivity 
-Fast response kinetics 
(working in vivo) 
 Nanoparticles: 
-Tumor-targeted delivery 
-Gene delivery 
Targeted drug delivery 
-Non-toxic to non-target cells 
-Overcoming blood brain barrier 
Successful control of 
physicochemical properties of 
delivery systems 
Inability to overcome biological 
barriers 
Need to overcome both 
physicochemical and biological 
barriers 
 
Different oral controlled release formulations were developed in order to achieve zero-order 
release. However, the zero-order release achieved in various in vitro dissolution systems did not 
result in maintenance of the constant drug concentration in vivo, mainly due to variations in the 
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drug absorption properties along the gastrointestinal tract (Yun et al., 2015). The drug release 
from a formulation in vivo is not only dependent on the formulation properties, but also on the 
biological environment surrounding the formulation (Yun et al., 2015). This fact makes the 
prediction of the drug release kinetics in vivo and bioavailability, more complicated (Yun et al., 
2015). In vivo-in vitro correlation (IVIVC) hasn’t been found for most parenteral formulations of 
biotech drugs, making it difficult to predict the in vivo bioavailability from the in vitro release 
profiles, especially for long term depot formulations (Cadot, 2009). Additionally, there are not 
standard in vitro drug release tests methods that can reliably predict in vivo pharmacokinetic 
profiles (Martinez et al., 2008). Shortly, the difficulty faced by 2G drug delivery systems is 
mainly due to inability of the drug delivery systems to struggle with biological barriers (Yun et 
al., 2015). The 3G drug delivery technologies will have to be advanced much beyond 2G 
technologies to overcome both physicochemical and biological barriers (Yun et al., 2015). Some 
of the barriers to overcome for developing successful 3G drug delivery systems are listed in 
Table 2. 
Table 2. Barriers to overcome by the 3G drug delivery systems 
Delivery technology Formulation barriers Biological barriers 
Poorly water soluble drug delivery -New excipients for increasing drug 
solubility 
-Non-toxic to the body 
-No drug precipitation in the blood 
-IVIVC 
-Long-term delivery up to year 
-Non-invasive delivery 
-Controlling biodistribution through 
altering vascular extravasation, renal 
clearance, metabolism, etc… 
-Navigating microenvironment of 
diseased tissues to reach target cells 
-Crossing endothelial barriers (e. g., 
blood-brain barrier) 
-Crossing mucosal barriers 
-Functional inside the body 
-Functional over the lifetime of drug 
delivery 
Peptide/protein/nucleic acid delivery 
Targeted drug delivery using 
nanoparticles 
-Control of drug release kinetics 
-Control of drug loading 
-Control of therapeutic period 
-Control of nanoparticle size, shape, 
surface chemistry, functionality and 
flexibility 
-Surface modification with ligands 
-Stimuli-sensitive delivery systems 
Self-regulated drug delivery -Signal specificity and sensitivity 
-Fast responsive kinetics 
-Ability to stop drug release 
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1.2. Delivery of poorly water-soluble drugs 
Poor water-solubility of drugs represents one of the most important issues in drug development 
nowadays (Yun et al., 2015). The descriptive terms used in US Pharmacopeia and National 
Formulary to announce approximate drug solubilities in water are shown in the Table 3. 
 
Table 3. Solubility definitions. 
Descriptive terms Parts of solvent required for one part 
of solute 
Solubility range 
mg/mL % 
Very soluble 
Freely soluble 
Soluble 
Sparingly soluble 
Slightly soluble 
Very slightly soluble 
Practically insoluble 
Less than 1 
From 1 to 10 
From 10 to 30 
From 30 to 100 
From 100 to 1000 
From 1000 to 10 000 
10 000 and over 
>1000 
100 - 1000 
33 – 100 
10 – 33 
1 – 10 
0.1 – 1 
≤ 0.1 
>100 
10 – 100 
3.3 – 10 
1 – 3.3 
0.1-1 
0.01-0.1 
≤ 0.1 
 
The term "poorly soluble" usually refers to the drugs that belong to "practically insoluble" group. 
Their aqueous solubility is 0.1 mg/mL or less. Many new drug candidates are poorly water 
soluble which disables them to be converted into clinically useful formulations (Yun et al., 
2015). According to the analysis of 200 orally administered drug products, practically insoluble 
drugs represent almost 40% of the total drugs (Takagi et al., 2006). Delivering these drugs 
effectively through the GI tract for therapeutically effective bioavailability is still an important 
problem (Yun et al., 2015). The dissolution rate of practically insoluble drugs may be so slow 
that dissolution takes longer than the GI transit time resulting in very low bioavailability (Horter 
et al., 2001). 
Technologies to dissolve poorly soluble drugs in water have been investigated for decades, and 
some of the approaches are shown in Table 4 (Yun et al., 2015). Poorly soluble drugs have 
inherently low water solubility, so appropriate excipients are added to increase the solubility. 
These usually include surfactants, polymer micells, hydrotropic agents, complexing agents (e. g., 
cyclodextrins and proteins), cosolvents, and lipid formulations (e. g., self-emulsifying systems) 
(Pouton, 2006, Kawabata et al., 2011, Lu et al., 2013). For weakly acidic or basic drugs, pH can 
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be controlled to increase the drug solubility (Yun et al., 2015). Alternatively, drug solubility and 
dissolution kinetics can be increased through the selection of appropriate polymorph, making 
solid dispersions (i. e. maintaining amorphous structure of the drug using polymers), reducing 
drug particle size and improving wetting with surfactants (Yun et al., 2015). 
 
Table 4. Methods to improve drug dissolution. 
Enhancing drug solubility Enhancing dissolution kinetics 
Using surfactant micelles 
Using polymer micelles 
Using hydrotropic agents 
Using complexing agents 
Using cosolvents 
Using self-emulsifying systems 
Controlling pH 
Selecting appropriate polymorph 
Making amorphous forms (solid dispersions) 
Reducing particle size (nanocrystals) 
Adding surfactant for better wetting) 
 
 
 
1.3. Fenofibrate 
 
Fenofibrate (propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate) (Figure 1) is a 
highly lipophilic drug used to normalize the plasma titer of low-density lipoproteins and 
cholesterol in patients with hypercholesterolemia and hypertriglyceridemia (Guay, 1993; Genest 
et al., 2002). 
Chemically it belongs to synthetic phenoxy-isobutyric acid derivates  (Source: PubChem: URL: 
https://pubchem.ncbi.nlm.nih.gov). 
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Figure 1. Chemical structure of fenofibrate (propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-
methylpropanoate) (Source: PubChem: URL: https://pubchem.ncbi.nlm.nih.gov) 
 
Mechanisms of action of fenofibrate include induction of lipoprotein lipolysis, induction of 
hepatic fatty acid uptake, reduction of hepatic triglyceride production, increased removal of LDL 
particles, reduction in neutral lipid (cholesteryl ester and triglyceride) exchange between LDL 
and HDL, increase in HDL production and stimulation of reverse cholesterol transport (Staels et 
al., 1998). Fenofibrate is indicated in primary hypertriglyceridemia, type III 
dysbetalipoproteinemia, primary hypercholesterolemia and non-insuline-dependent diabetes 
mellitus (Staels). As a typical Biopharmaceutical Classification System class 2 compound (log p 
¼ 5.24), it is virtually insoluble in water and physiological fluids (Ming-Thau et al., 1994). Its 
insufficient absorption from the aqueous environment of the gastrointestinal tract results in very 
low systemic exposure after oral administration (Guay, 1993). Thus, oral bioavailability of 
fenofibrate may be improved by increasing its aqueous solubility (Yousaf et al., 2015). Although 
over the past few years, several conventional formulation techniques, such as micro- and 
nanonization (Hens et al., 2015) formation of liposomes (Chen et al., 2009) various polymeric 
nanoparticulated systems (Yousaf et al., 2015) and lipid-based formulations (Fei et al., 2013) 
have been employed to enhance the oral bioavailability of fenofibrate, the number of marketed 
applications of these technologies remains very limited. 
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1.4. Ordered mesoporous silica 
 
Ordered mesoporous silica materials (Figure 2) with different arrangement of mesopores have 
been intensively examined for a broad spectrum of applications such as molecular separation, 
optics, drug delivery, catalysis and template nanotubes synthesis (Corma, 1997; Scott et al., 
2001; Vallet-Regi et al., 2007; Zheng et al., 2002; Taguchi et al., 2005). During the last decade 
the focus of interest for ordered mesoporous silicates has been shifted to drug delivery systems 
for poorly soluble drugs (Van Speybroeck et al., 2010).  
 
 
 
 
 
Figure 2. Ordered mesoporous silica (SBA-15 material). Left: High resolution FESEM image of 
the pore structure of SBA-15; Right: Representation of the pore arrangement (Kleitz 2009). 
 
The synthesis of ordered mesoporous silicates is being performed in basic or acidic conditions 
via a sol-gel derived process where surfactants or polymers serve as a template for the 
polymerizing silica (Kresge et al., 1992; Zhao) (Figure 3). When the polymerization of the silica 
is complete, the template can be eliminated through either chemical or thermal treatment, which 
consequently induces porosity (Van Speybroeck et al., 2010). Owing to this template-assisted 
synthesis, the end product has very narrow pore size distribution (Van Speybroeck et al., 2010). 
Additionally, these materials have a very high specific surface area (up to 1500 m2/g) and pore 
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volume (up to 1.5 cm3/g). Through careful selection and optimization of the synthesis conditions, 
the pore diameter and particle morphology of silica material can be adjusted to the requirements 
of the user (Grun et al., 1999; Zhao et al., 2000).  
 
 
 
Figure 3. Schematic representation of liquid crystal mechanism used to describe the synthesis of 
silica-based ordered mesoporous materials (Colilla et al., 2008). 
 
 
The pore size of mesoporous silica can be controlled by using swelling agents, surfactants with 
different chain length and hydrothermal restructuring (Corma et al., 1997). With respect to the 
three above mentioned synthetic strategies for pore tailoring, adding of swelling agents and 
changing the length of the surfactant micelle are the most widely used for the pore size control 
(Xu et al., 2013). Using these approaches, the pore diameters can be increased by 0-10 nm 
depending on the used procedures (Xu et al., 2013). On the other hand, the change in the pore 
diameter is only within 1 nm if hydrothermal restructuring has been applied (Corma et al., 
1997). The most frequently used swelling agents include hydrophobic organic compounds such 
as trimethylbenzene and hexane (Xu et al., 2013). The mechanism of action for these molecules 
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is based on the penetration into the cores of the amphiphilic surfactant micelles to enlarge the 
size of template micelles (Boissiere et al., 2003). For instance, Kruk and Cao successfully 
synthesized highly ordered SBA-15 with adjustable pore diameters in the range from 9.4 to 18.2 
nm with the usage of hexane (Kruk et al., 2007). Hydrophilic anions like organic amines or 
inorganic salts can also be considered as pore swelling agents (Xu et al., 2013). One of good 
examples is study performed by Sayari et al (1999) where amines were added as expanders in 
direct synthesis and post synthesis procedures to expand the pore size of MCM-41 materials 
(Sayari et al., 1999). The pore size adjustment in the range from 3.5 to 7.5 nm was achieved by 
adding appropriate amounts of N, N-dimethylhexadecylamine. Even though the easiest way to 
control the pore size is changing the length of the surfactant micelle, this strategy is not always 
feasible due to the limited availability of commercial surfactants (Xu et al., 2013). 
Another important concern in the development of mesoporous silica materials for biomedical 
applications is controlling the particle morphology (Xu et al., 2013). Studies have shown that 
inorganic or organic additives, hydrolysis and condensation of silicates, and the shapes of 
surfactant micelles are the main factors affecting the morphology of silica particles (Du et al., 
2009). Varying of these parameters enables the synthesis of the mesoporous silica with the 
different morphologies such as fibers, spheres and rods (Xu et al., 2013). Study performed by 
Grun et al. (1999) investigated the effect of short chain alcohols like ethanol and isopropanol on 
the morphology of MCM-41 (Grun et al., 1999). Usage of short chain alcohol as a co-solvent 
gives a homogeneous system which leads to the formation of spherical MCM-41 particles. 
Subsequent studies (Yu et al., 2004; Zhao et al., 2000) explained the mechanism of morphology 
control. It was discovered that the morphology of SBA-15 was very dependent on surface 
curvature energy at the interface of inorganic silica and organic block copolymer species. The 
addition of polar co-solvent, co-surfactant and concentrated strong inorganic salts can lower the 
local curvature energy and ease the formation of highly curved particle morphologies for SBA-
15 such as doughnut-, sphere-, gyroid-, and discoid-like particles (Wan et al., 2007). 
 
The term mesoporous refers to the materials that have pores with a diameter in the mesopore size 
range from 2 to 50 nm (Van Speybroeck et al., 2010). The term ordered designates that these 
materials are characterized by long-range ordering, even though their pore walls consist of 
amorphous silica. Because of their unique features, ordered mesoporous silicates are very 
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efficient in the enhancement of drug dissolution (Van Speybroeck et al., 2010). Numerous 
studies have shown that drugs lose their crystallinity when they are deposited onto the surface of 
mesoporous silicate, which consequently improves their dissolution rate (Charnay et al., 2004, 
Heikkila et al., 2007, Mellaerts et al., 2010). Mesoporous silicates have an advantage in 
comparison with the non-porous high surface area materials. The deposited molecules are not 
just adsorbed onto the silica surface, but also confined to the pores that are only a few molecular 
diameters wide, which inhibits the recrystallization of the drug molecules (Alba-Simionesco et 
al., 2006). 
Consequent to influx of water, the adsorbed drug molecules are being removed from the silica 
surface and diffuse out of the pores (Mellaerts et al., 2008). In the case of poorly soluble drugs, 
this gives concentrations that are not achievable by dissolution of the low-energy crystalline 
form (Van Speybroeck et al., 2010). 
 
Table 5. Poorly soluble drugs studied on mesoporous materials. 
 
Drug 
MW 
(g/mol) 
Solubilitya 
(mg/mL) 
Carrier 
Particle 
size (µm) 
Drug 
loading 
capacity 
(wt. %) 
In 
vitro 
In 
vivo 
Ref. 
Atazanavir 704.9 4.0-5.0 NFM-1 
AMS-6 
STA-11 
10.16 
9.44 
9.85 
28.2 
31.5 
32.8 
    x     x Xia et al. (2012) 
Carvedilol 406.5 0.583 SBA-16 
MCM-41 
TiO2 
Hydroxycarb
onate apatite 
2.0-3.0 
1.0 
0.15/0.30 
0.20-0.30 
25.0 
25.0 
22.8/23.9 
22.5-48.7 
   x 
 Hu et al. (2012) 
Hu et al. (2012) 
Jiang et al. (2012) 
Zhao et al. (2012) 
Celecoxib 381.4 0.003 Carbon 0.5-
0.8/5.0-
40.0 
28.5-37.5 
  x    x 
Zhao et al. (2012) 
Ezetimibe 409.4 0.0085b SBA-15 Nc 17.9   x    x Kiekens et al. (2012) 
Fenofibrate 360.8 0.25 SBA-15 
 
MCM-41 
N 
 
N 
20.0/40.0 
 
20.0 
   x 
 Van Speybroeck et al 
(2010) 
Van Speybroeck et al 
15 
 
 
SBA-15 
 
0.2-1.0 
 
21.5 
(2010) 
Van Speybroeck et al 
(2009) 
Flurbiprofen 244.3 0.008 FSM-16 N 30.0    x  Tozuka et al. (2005) 
Furosemide 330.7 0.25 TCPSi 
 
TCPSi 
 
TOPSi 
N 
 
<38.0 
 
<38.0 
39.0 
 
41.3 
 
41.3 
   x 
 Kaukonen et al. 
(2007) 
Salonen et al. (2005) 
Salonen et al. (2005) 
Glibenclamide 494.0 0.004 SBA-15 N 22.5 
   x    x 
Van Speybroeck et 
al. (2011) 
Griseofulvin 352.8 0.009 TCPSi 
TCPSi 
TOPSi 
<38.0 
<38.0 
0.17 
16.5 
16.5 
17.3 
   x 
 Salonen et al. (2005) 
Salonen et al. (2005) 
Bimbo et al. (2011) 
Ibuprofen 206.3 0.049 Psi 
TCPSi 
TOPSi 
THCPSi 
Spherical 
mesoporous 
silica 
TCPSi 
MCM-41 
SBA-15 
APTES 
modified 
SBA-15 
<38.0 
<38.0 
<38.0 
<38.0 
0.5-0.95 
 
 
<38.0 
<38.0 
~50.0 
N 
 
N 
36.8 
30.9 
36.5 
31.9 
21.3-24.3 
 
 
29.3 
10.5/37.2 
50.4 
16.9-37.2 
 
41.0 
   x 
 Limnell et al. (2007) 
Limnell et al. (2007) 
Limnell et al. (2007) 
Limnell et al. (2007) 
Xu et al. (2009) 
 
 
Hekkila et al. (2007) 
Hekkila et al. (2007) 
Hekkila et al (2007) 
Song et al. (2005) 
Indomethacin 357.8 0.0009 Syloid 244 
MCM-41 
3DOM 
SBA-15 
 
TOPSi 
2.5-3.7 
<125 
N 
0.1-1.0 
 
13.6 
28.9 
27.0 
25.0-50.0 
18.6 
 
5.6 
   x 
  
 
 
  x 
  x 
Limnell et al. (2011) 
Limnell et al. (2011) 
Hu et al. (2011) 
Van Speybroeck et 
al. (2009) 
Wang et al. (2010) 
Itraconasole 705.6 0.0096b Syloid AL-1 
Syloid AL-
244 
TOPSi 
6.5-8.1 
2.5-3.7 
 
25.0-75.0 
21.0/25.1 
21.9/32.8 
 
11.2 
   x 
 
 
 
Kinnari et al. (2011) 
Kinnari et al. (2011) 
 
Kinnari et al. (2011) 
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TCPSi 
SBA-15 
 
COK-2 
 
SBA-15 
25.0-75.0 
13.8 
 
19.0 
 
0.2-1.0 
11.3 
19.1 
 
18.1 
 
21.3 
 
 
 
 
 
   x 
Kinnari et al. (2011) 
Vialpando et al. 
(2011) 
Vialpando et al. 
(2011) 
Mellaerts et al. 
(2008) 
Lovastatin 404.5 0.0004 Mesoporous 
carbon 
5.0-40.0 25.6-36.3    x 
 Zhao et al. (2012) 
Telmisartan 514.6 0.0035b MCM-41 
SBA-15 
~0.05/1.0
-2.0 
27.5    x    x 
Zhang et al. (2012) 
Carbamazepine 236.3 0.018 
SBA-15 0.0-1 
22.5 
   x 
 
Van Speybroeck et al 
(2009) 
Cinnarizine 368.5 0.75 20.7 
Danazol 337.5 0.018b 20.9 
Griseofulvin 352.8 0.0086 19.7 
Ketoconazole 531.4 0.00009 20.4 
Nifedipine 346.3 0.018b 20.7 
Phenylbutazone 308.4 0.048 19.8 
aSolubility based on experiments in water at 25ºC unless otherwise stated. 
bPractically insoluble in water at 25ºC. The solubility is predicted based on theory. 
c(N) The particle size was not mentioned in the study. 
All the examined drugs except furosemide (BSC class IV) belong to BSC class II.  
 
1.4.1. Methods of drug loading 
 
Due to low concentration of the poorly soluble drugs in aqueous solution, the loading of drugs 
into the mesoporous carriers is performed with the method of organic solvent immersion, 
incipient wetness impregnation or the melt method (Mellaerts et al., 2008). According to the 
available literature, solvent immersion has been most frequently used (Xu et al., 2013). The drug 
loading process of mesoporous materials by immersion includes three steps: (1) immersing 
mesoporous materials into concentrated drug solution and filling of the pores through capillary 
action, (2) diffusion of drug molecules into the mesopores and their adsorption on the pore walls, 
(3) collecting of the drug loaded mesoporous materials from the solution (Xu et al., 2013). 
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Incipient wetness impregnation is a technique where very concentrated drug solution is used to 
achieve a high loading degree (Xu et al., 2013).  The volume of the drug solution equals to the 
pore volume of mesoporous carriers, which is one of the main differences in comparison with the 
immersion method (Xu et al., 2013). In both cases capillary action is responsible for the 
withdrawal of the solution and dissolved drug molecules into the pores (Xu et al., 2013). The 
impregnation method is chosen when small amounts of drug are available (Xu et al., 2013). It is 
simple to determine the amount of the loaded drug in advance, however it is complicated to 
control the uniformity of the drug distribution (Xu et al., 2013). Another disadvantage is that the 
residual drug can re-crystallize on the external surface of mesoporous materials after solvent 
evaporation (Xu et al., 2013). 
The melt method assumes the heating of physical mixture of the drug and mesoporous carrier 
above the melting point of the drug (Xu et al., 2013). This method could be considered as a 
special case of the impregnation method (Xu et al., 2013). Unfortunately, for many drugs 
melting is usually followed with the degradation (Xu et al., 2013). Also in some cases, high 
viscosity of the melted drug can be limiting factor for successful drug loading (Xu et al., 2013). 
There are several factors that can influence the loading degree of the drug when the molecules 
are loaded in the confined space of the mesopores (Xu et al., 2013). The maximum loading 
degree which can be defined as the ratio of the drug mass to the total mass of the drug when the 
pores are completely filled, sometimes can be predicted on the basis of the pore volume of 
mesoporous carrier and the packing density of the payload drug (Xu et al., 2013). High loading 
degrees such as 60 wt. % can be obtained for the carriers with very high porosity (Xu et al., 
2013). The loading method have an influence on the achieved loading degree, the packing of the 
molecules in the pores and their distribution in the carrier (Xu et al., 2013). 
In terms of the loading of the drugs in mesoporous carriers, one of the most critical decisions is 
to choose appropriate loading conditions so that the drug molecules do not degrade due to the 
treatment (Xu et al., 2013). Concerning this, the right choice of the solvent and the chemical 
surface properties of the carrier are essential (Xu et al., 2013). If the fast release of the drug 
molecule is required there must not be any strong interaction between the payload molecules (Xu 
et al., 2013). The pore size should also be adjusted to ease the diffusion of the molecules out 
from the pores (Xu et al., 2013). The most important point in an improving the dissolution 
behavior is a reduction of the lattice energy of well-ordered crystalline structures by creating 
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amorphous or disordered structures by confining the drug molecules in a restricted space (Xu et 
al., 2013). The factors that can affect drug loading degree are described in the following sections. 
 
1.4.1.1. Effect of pore size 
 
The pore size is essential for the drug loading because the mesopores basically represent 
molecule sieves and in this manner they can determine how large molecules can be loaded into 
the carrier materials (Xu et al., 2013). The ratio of pore diameter/drug molecule size must be >1 
so that the pores are accessible for drug molecules (Xu et al., 2013). Additionaly, if the full 
usage of surface area and high drug loading is required, the ratio should be higher than 3 (Xu et 
al., 2013). Mesoporous MCM-41 with different pore sizes was produced by varying surfactant 
molecules with different lengths of alkyl chain and then the effect of pore size on the drug 
loading was investigated (Horcajada et al., 2004). The results showed that after immersing 
mesoporous MCM-41 in a hexane solution with ibuprofen (molecule size 1 nm x 0.5 nm), higher 
loading efficiency was achieved with the pore size of 3.6 nm (loading degree of 19 wt. %) in 
comparison with a pore size of 2.5 nm (11 wt.%). Another poorly soluble drug, telmisartan, 
examined on the spherical mesoporous silica, showed an increase in the loading degree from 49 
% to 60 % as the pore size changed from 3.6 to 12.9 nm (Zhang et al., 2010). 
 
1.4.1.2. Effect of surface area and pore volume 
 
When the drug molecules adsorb on the surfaces of mesoporous materials, they can form a 
monolayer or multilayers on the surfaces (Xu et al., 2013). If the drug forms monolayer, the 
loading capacity is directly proportional to the surface area (Xu et al., 2013). In that case, the 
pore volume of the materials doesn’t have any influence on the drug loading (Xu et al., 2013). 
The forming of the drug monolayer can be described with a Langmuir isotherm (Andersson et 
al., 2004). However, if there is a significant interaction between the drug molecules, or if a 
highly concentrated drug solution is used, the drug molecules form multimers or multilayers on 
the surface of the pores (Xu et al., 2013). So in this case, both the surface area and the pore 
volume can influence the drug loading capacity (Zhang et al., 2010) 
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1.4.1.3. Effect of surface chemistry 
 
The interfacial interactions between the surface of mesoporous materials and the drug molecules 
represent the driving force for the drug loading (Xu et al., 2013). Physical and chemical 
adsorption are the two common mechanisms which are mostly determined by surface chemistry 
of mesoporous carriers (Xu et al., 2013). In the case of poorly soluble drugs, physical adsorption 
is preferred if improved drug dissolution is required since this is a reversible process (Xu et al., 
2013). Usual forms of the physical adsorption between drugs and mesoporous carriers are 
hydrogen bonding, electrostatic and hydrophobic interactions (Xu et al., 2013). Unmodified 
mesoporous carriers have the surface covered with –OH groups, so hydrogen bond is expected 
form of the interaction (Salonen et al., 2008). Surface functionalization can induce electrostatic 
or hydrophobic interactions, which either increases or decreases the drug loading efficiency of 
the carriers (Xu et al., 2013). For example, on mesoporous Al2O3 (Kapoor et al., 2009), 
functionalization with hydrophobic Si-CH3 groups resulted in a lower loading degree of 
ibuprofen (approximately 20%) whereas hydrophilic groups gave significantly higher drug 
loading efficiency. The same study showed that highest drug loading (about 45%) was achieved 
after (3-aminopropyl)-triethoxysilane (APTES) modification. Improved drug loading capacity 
was explained with the electrostatic interaction between –NH on modified carriers and the –
COOH of ibuprofen. So, it may be concluded that the surface modification method can 
significantly contribute to the drug loading capacity (Song et al., 2005).  
 
1.4.1.4. Effect of solvent 
 
The polarity of solvent also can influence the drug loading (Xu et al., 2013). As it was previously 
mentioned, a dominant interaction between drug molecules and the surface of carriers for 
unmodified mesoporous silica materials is hydrogen bonding (Xu et al., 2013). Very polar 
solvents such as dimethyl sulfoxide (DMSO), can be in the competition with the drug molecules, 
which can adversely affect the drug loading (Xu et al., 2013). The effect of solvent on the 
loading of poorly soluble drug has been studied with numerous solvents including 
dimethylformamide (DMF), dimethylacetamide (DMA), DMSO, ethanol and hexane (Charnay 
et al., 2004). Ibuprofen was not adsorbed onto MCM-41 surface in DMA due to its extreme 
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polarity. On the other hand, in hexane, the loading capacity was up to 37% wt. The solvent effect 
has a similar influence on silicon, Al2O3 and TiO2 based mesoporous materials because of their 
polar surface properties (Xu et al., 2013). For carbon based mesoporous materials with the 
nonpolar surface, the adsorption of drug molecules is enhanced from the solvent with high 
polarities (Xu et al., 2013). 
 
1.4.2. Characterization of drug loaded carriers 
 
The characterization of drug-loaded carriers includes: drug-carrier interactions, the amount of the 
loaded drug (loading degree/efficiency) and physical characteristics of the loaded drug (Xu et al., 
2013). Drug-carrier interactions are usually examined by Fourier transform infrared spectroscopy 
(FTIR) or by defining the absorption isotherms of the drug, which can reveal significant 
information about the possible chemisorption or physisorption on the carrier surface (Jarvis et 
al., 2011). 
Drug loading degree of the carrier is commonly determined by the extraction and 
thermogravimetry (TG) (Xu et al., 2013). After the extraction that is performed to release the 
drug from the carrier, the drug concentration in the medium is measured which gives the 
information about the total loading degree (Xu et al., 2013). The most frequently used technique 
for drug concentration assay is high performance liquid chromatography (HPLC) since it can 
additionally give information about the possible degradation of the payload molecules (Xu et al., 
2013). UV/VIS spectroscopy is an alternative method for the determination of the drug 
concentration for the drug molecules with absorption in the range of ultraviolet or visible light 
(Xu et al., 2013). If the mentioned techniques are applied, care should be taken that payload 
material has been extracted completely from the carriers. Very often the release can be 
incomplete (Xu et al., 2013). Thermogravimetric analysis assumes the measurement of the 
weight of the sample in the function of temperature (Xu et al., 2013). It is easy to observe the 
mass of the loaded drug since the thermal decomposition of the organic drug occurs at lower 
temperatures than decomposition of the carrier (Xu et al., 2013). 
During the characterization process it is very important to become familiar with the state of the 
drug in the mesoporous carriers (Xu et al., 2013). Poorly soluble drug that is adsorbed on the 
external surface of the carrier particle can stop the release of the drug and have a negative 
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influence on the release rate of the drug (Xu et al., 2013). This drug material that is located 
outside the pores can be easily distinguished from the drug inside the pores by the size of the 
crystallites (Xu et al., 2013). In the pores, the crystalline size is limited by the pore walls 
whereas outside the pores such restraints do not exist and crystallites tend to grow significantly 
larger (Xu et al., 2013). The physical state of the drug is usually characterized by XRD and 
differential scanning calorimeter (DSC) (Heikkila et al., 2007). Both methods can be applied to 
detect crystalline phases as well as size of the crystallites in the loaded materials (Xu et al., 
2013). Additionally, some other techniques such as pycnometry, nitrogen sorption and NMR can 
be used to gain an information about the loaded drug (Babonneau et al., 2004). 
Drug inside the pores can be in an amorphous or in different crystalline phases (Xu et al., 2013). 
It has been confirmed that the drug confined in small, few nm wide pores drugs is in an 
amorphous state (Van Speybroeck et al., 2009). The amorphous state can be dispersed on the 
pore walls of the material leaving the center of the pore free or it can fill the center of the pore 
(Mellaerts et al., 2008). The amorphous compounds, ibuprofen and indomethacin, are highly 
mobile in the pores at least when they form a thin layer on the surface without strong drug-
carrier interactions (Azais et al., 2006). 
It is important to note that the crystallization of the loaded drugs is not possible as long as the 
critical nucleus is bigger than the pore (Xu et al., 2013). In this case, it would be energetically 
unfavourable for a nucleus to grow, i. e. the drug to crystallize in the pores (Xu et al., 2013). If 
the pore and the drug cluster in the pore are larger than the critical nucleus, crystallization is 
possible (Xu et al., 2013). Crystals of the drug inside the pores have significantly different 
properties compared with bulk crystals (Xu et al., 2013). It is well known that the crystal size 
affects the solubility or a melting temperature of the material (Xu et al., 2013). Additionally, 
loaded drug does not crystalize completely, but a thin non crystallizing layer, the known as δ-
layer, appears always between the pore wall and crystalline core (Riikonen et al., 2009). 
Confinement in the mesopores can also affect the crystal structure of the drug (Xu et al., 2013). 
It has been observed that crystal structures that are unstable in bulk can become stable in the 
mesoporous because the relative stability of the polymorphs can be dependent on the size of the 
crystals (Rengarajan et al., 2011). One of the studies even reported that previously unknown 
polymorphs have been detected to be formed under confinement (Ha et al., 2009). Furthermore, 
the crystal orientation in the pores may not be random (Xu et al., 2013).  
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1.4.3. Drug release and mechanism studies 
 
Poorly water soluble drugs are known to have numerous of negative clinical effects, such as rate-
limiting dissolution, slow absorption and low bioavailability (Xu et al., 2013). One of the most 
important issues is that these drugs tend to be eliminated from the gastrointestinal tract before 
they have the opportunity to fully dissolve and be absorbed into the systemic blood circulation 
(Xu et al., 2013). Consequently, the dosage of poorly soluble drugs should be very high to reach 
a required therapeutic drug concentration in blood, which can induce local toxicity and 
discomfort on patients (Xu et al., 2013). 
  
1.4.3.1. In vitro studies 
 
The first goal for the delivery of poorly soluble drugs is to increase their dissolution rate in 
biological fluids (Xu et al., 2013). Several factors have an influence on the drug release from 
mesoporous carrier (Xu et al., 2013). Since the release of the drug molecules is mainly controlled 
by the diffusion mechanism, the effect of pore size plays an important role (Xu et al., 2013). For 
example, in the system of ibuprofen loaded MCM-41, the drug release rate decreased clearly as 
the pore size changed from 3.6 to 2.5 nm (Horcajada et al., 2004). The pore size effect was 
further verified on the model drug indomethacin, which was loaded in the mesoporous SBA-16. 
The amount of the drug released from the pore sizes of 4.3 nm, 6.8 nm and 9.0 nm were 75%, 
81% and 90 % within 60 minutes, respectively (Hu et al., 2011).  
Another important factor that have an influence on the release rate is the surface chemistry (Xu 
et al., 2013). The release rate of celecoxib from mesoporous carbon was found to be higher than 
from SBA-15 (Zhao et al., 2012). Post-grafting of alkyl groups increased the surface 
hydrophobicity, so the diffusion of H2O molecules from the biological fluids into the pores was 
slower. Consequently, the release of drug from mesoporous carriers decreased (Xu et al., 2009). 
Finally, the pore architectures of mesoporous carriers also affected drug release rate (Xu et al., 
2009). Due to the 3D connected pore structure of SBA-16 and TUD-1, these samples exhibited 
faster drug release than the mesoporous carriers such as MCM-41with 2D pore channels (Hu et 
al., 2012). The 3D mesoporous structure obviously provided more favourable mass transfer 
which simplified drug release without pore blocking (Xu et al., 2009). 
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1.4.3.2. In vivo studies 
 
Improving the bioavailability of poorly soluble drugs in biological fluids is one of the greatest 
challenges for pharmaceutical scientist today (Xu et al., 2009). Animal tests play an important 
role in the formulation development due to the poor correlation frequently observed between the 
in vitro and in vivo results (Xu et al., 2009). Unfortunately, many of the studies are limited only 
to in vitro evaluations or in the best case on the experiments conducted with cells (Xu et al., 
2009). 
Poorly soluble drugs loaded into mesoporous materials are in an amorphous form and in vitro 
tests usually show the enhanced drug dissolution (Xu et al., 2009). Therefore, an improved 
bioavailability could also be expected in in vivo tests (Kiekens et al., 2012). For example, an 
enhanced in vivo pharmacokinetics was successfully confirmed with indomethacin loaded 
TOPSi. The study revealed that the value of Tmax was reduced to a one fourth, Cmax increased 200 
% and bioavailability was significantly enhanced when the mesoporous carrier was used in 
comparison with either pure indomethacin or commercially available product Indocid (Wang et 
al., 2010). Another study performed by Mellaerts et al., (2008) investigated the in vivo 
performance of ordered mesoporous silica for itracinasole in two animal species - rabbits and 
dogs. After oral administration of crystalline itraconasole to dogs (20 mg), no systemic 
itraconasole could be detected; on the other hand, the area under the curve 0-8 h (AUC0-8) was 
681 ± 566 nM h when the drug was formulated with the mesoporous carrier. In rabbits, the 
AUC0-24 increased to 1069 ± 278 nM h and Tmax decreased from 9.8 ± 1.8 to 4.2 ± 1.8 h  , when 
the SBA-15 was employed. Mesoporous carbon also showed an enhanced bioavailability of 
poorly soluble drug celecoxib when it was used as the carrier (Zhao et al., 2012). Results 
showed that the AUC0-24 of celecoxib loaded in mesoporous carbon was about 1.68-fold of that 
for commercial celecoxib capsules (Pfizer Pharmaceuticals LLC). These are just some of the 
examples where the subsequent in vivo studies confirmed the in vitro results. 
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1.5. Sodium diclofenac 
 
Sodium diclofenac (sodium; 2-[2-(2,6-dichloroanilino)phenyl]acetate) (Figure 4) belongs to a 
group of nonsteroidal anti-inflammatory drugs (NSAID) of the phenylacetic acid class with 
combined anti-inflammatory, analgesic and antipyretic properties (Altman et al., 2015). 
Chemically diclofenac sodium is the sodium salt form of diclofenac, a benzene acetic acid 
derivate (Source: PubChem: URL: https://pubchem.ncbi.nlm.nih.gov) 
 
 
 
Figure 4. Chemical structure of sodium diclofenac (sodium; 2-[2-(2,6-
dichloroanilino)phenyl]acetate). (Source: PubChem: URL: https://pubchem.ncbi.nlm.nih.gov) 
 
 
Opposed to the action of many traditional NSAIDs, diclofenac inhibits cyclooxygenase (COX)-2 
enzyme stronger than it does COX-1 (Altman et al., 2015). The mechanism of action is based on 
the binding of diclofenac to COX isozymes and inhibition of the synthesis of prostanoids (i. e., 
prostaglandin (PG)-E2, PGD2, PGF2, prostacyclin (PGI2) and thromboxane (TX) A2 (Vane, 
1971). PGE2 is the dominant prostanoid produced in inflammation, and the inhibition of its 
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synthesis by NSAIDs is assumed to be the main reason for the potent analgesic and anti-
inflammatory features of these drugs (Patrono et al., 2001). 
After oral administration, systemic absorption of diclofenac is generally very fast and directly 
proportional to the dose (Davies et al., 1997). Approximately 60% of the intact diclofenac enters 
the systemic circulation due to first-pass metabolism (Todd et al., 1988). It has been confirmed 
that the main metabolite, 4’-hydroxydiclofenac has weak anti-inflammatory and analgesic 
activities (Fowler et al., 1983). Finally, after the biotransformation to glucoroconjugated and 
sulphate metabolites, diclofenac is excreted in the urine (Todd et al., 1988). 
Diclofenac, as the other NSAIDs, can cause serious dose-related gastrointestinal, cardiovascular 
and renal side effects (Brater et al., 2002, Lewis et al., 2002, Salvo et al., 2011). The main cause 
of the gastrointestinal adverse effects is decreased synthesis of prostanoids and consequent  
limited secretion of mucus and bicarbonate that normally protect the gastric mucosa from 
damage (Sinha et al., 2013). PGI2 which is known to be a major product of COX-2-mediated 
metabolism of arachidonic acid in vascular endothelial cells, act as a potent vasodilator and 
platelet inhibitor (Patrono et al., 2014). Extensive clinical and preclinical studies indicate that 
suppression of PGI2 synthesis significantly increases the risk for hypertension and thrombosis 
(Yu et al., 2012). 
 
1.6. Erythrocyte ghosts as controlled drug delivery systems 
 
Erythrocytes represent the most abundant cells in the human body (~5.4 million cells/mm3 blood 
in a healthy male and ~4.8 million cells/mm3 blood in a healthy female (Gothoskar, 2004). These 
cells were described in human blood samples by Dutch scientist Lee Van Hock in 1674 
(Gothoskar, 2004). Erythrocytes have the shape of the biconcave disc with an average diameter 
of 7.8 µm, a thickness of 2.5 µm in periphery, 1µm in the center, and a volume 85-91 µm3 
(Guyton, 1996). The flexible, biconcave shape enables erythrocytes to squeeze through narrow 
capillaries, which may be only 3 µm wide (Gothoskar, 2004). Mature erythrocytes have very 
simple structure, they do not contain a nucleus and other organelles (Gothoskar, 2004). Their 
plasma membrane encloses hemoglobin, a heme-containing protein that is responsible for O2-
CO2 binding inside the erythrocytes (Gothoskar, 2004). Erythrocytes have the role in the 
transport of O2 from the lungs to tissues and the CO2 produced in the tissues back to lungs 
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(Gothoskar, 2004). Thus, erythrocytes represent highly specialized O2 carrier system in the body 
(Gothoskar, 2004). 
The life span of erythrocytes is approximately 120 days (Gothoskar, 2004). Old erythrocytes are 
being eliminated from circulation and destroyed in the spleen and liver (RES) (Gothoskar, 
2004). Within the body, erythrocytes are produced in red bone marrow under the regulation of 
hemopoietic hormone erythropoietin in the process called erythropoiesis (Torotra et al., 1993). 
 
 
1.6.1. Source and isolation of erythrocytes 
 
Different types of mammalian erythrocytes have been used as drug delivery systems, including 
erythrocytes of mice, cattle, pigs, dogs, sheep, goat, monkeys, chicken, rats and rabbits 
(Gothoskar, 2004). The first step in isolation of erythrocytes is collection of the blood in 
heparinized tubes by venipuncture (Gothoskar, 2004). Fresh whole blood is preferably used for 
loading purposes because it has been shown that the encapsulation efficiency of the erythrocytes 
isolated from fresh blood is higher than that of the aged blood (Gothoskar, 2004). Fresh whole 
blood is defined as the blood that is collected and immediately chilled to 4 ºC and stored for less 
than two days (Gothoskar, 2004). The erythrocytes are then separated and washed by 
centrifugation (Gothoskar, 2004). The washed cells are suspended in buffer solution at various 
hematocrit values as required and are usually stored in acid-citrate-dextrose buffer at 4 ºC for as 
long as 48 h before use (Gothoskar, 2004). The detail protocol for the isolation of erythrocytes 
has been established by Jain and Vyas (Vayas et al, 2002). 
 
1.6.2. Advantages of erythrocytes as drug carriers 
 
The most important feature of erythrocytes as drug carriers is their biocompatibility, particularly 
when autologous cells are used, eliminating possibility of triggered immune response (Lewis, 
1984). Erythrocyte membranes are biodegradable and do not generate toxic products (Lewis, 
1984). These carriers have considerably uniform size and shape (Telen, 1993) and relatively 
inert intracellular environment (Adriaenssens, 1976). The wide variety of chemicals can be 
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entrapped (Jaietely et al., 1996, Sprandel, 1987) with possibility to modify pharmacokinetic and 
pharmacodynamic parameters of drug (Jain, 1997). Large quantity of drug can be encapsulated 
within a small volume of cells ensuring dose sufficiency (Vyas et al., 2002). These carriers allow 
attainment of steady-state plasma concentration of drug, decrease fluctuations in concentration 
(Lewis, 1984) and consequently eliminate side effects (Lewis et al., 1984). They have ability to 
target organs of RES (Lewis, 1984) and offer the possibility of ideal zero-order drug-release 
kinetics (Eichler, 1986). Techniques and facilities for isolation, separation, handling, transfusion 
and working with erythrocytes are very well developed and available (Lewis, 1984). 
 
1.6.3. Methods of drug loading 
 
There are several methods that can be used to load drugs or other bioactive entities in 
erythrocytes and they can be roughly divided on physical osmosis-based systems and chemical 
methods (Gothoskar, 2004). Independently of the method used, successful entrapment of the 
compound requires the drug to have high water solubility, resistance against degradation within 
erythrocytes, lack of physical and chemical interaction with erythrocyte membrane, as well as 
defined pharmacokinetic and pharmacodynamic properties (Hamidi et al., 2003). 
Hypotonic hemolysis is a process based on the intrinsic ability of erythrocytes to reversibly swell 
in a hypotonic solution (Gothoskar, 2004). Erythrocytes can reversibly change their shape with 
or without accompanying volume change and can undergo reversible deformation under stress 
(Gothoskar, 2004). An increase in volume induce a change in the shape from biconcave to 
spherical (Gothoskar, 2004). The cells obtain a spherical shape to accommodate additional 
volume while keeping the surface area constant (Gothoskar, 2004). An increase in volume is 
approximately ~25-50% (Gothoskar, 2004). The upper limit of tonicity for cells to maintain their 
integrity is ~150 mosm/kg, above which the membrane ruptures, releasing hemoglobin and other 
cellular content (Gothoskar, 2004). At this point (just before cell lysis), some transient pores of 
200-500 Å appear on the membrane (Gothoskar, 2004). After cell lysis, cellular contents are 
released and residual material represent an erythrocyte ghost (Jain, 1997). These ruptured 
erythrocytes can be used as drug vechicles because ruptured membranes can be easily resealed 
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by bringing back the cells into the isotonic conditions (Gothoskar, 2004). After the incubation, 
the cells recover their original biconcave shape and original impermeability (Ihler et al., 1987). 
Alternative approaches for the drug loading include use of red cell loader (Magnani et al., 1998), 
hypotonic dilution (Iher et al., 1973), hypotonic preswelling (Rechsteiner, 1975), hypotonic 
dyalisis (Klibansky, 1959), isotonic osmotic lysis (Bird et al, 1983), chemical perturbation of the 
membrane (Deuticke et al, 1973), electro-insertion or electroencapsulation (Zimmermann, 
1975), entrapment by endocytosis (Schrier, 1976), loading by electric cell fusion (Tsong et al., 
1985) and loading by lipid fusion (Nicolau et al., 1979). 
 
1.6.4. Applications of resealed erythrocytes 
 
Erythrocytes and erythrocyte ghosts have broad spectrum of applications in various fields of 
human and veterinary medicine (Gothoskar, 2004). 
 
 
1.6.4.1. Slow drug release 
 
Numerous studies reported the usage of erythrocytes for the sustained delivery of antineoplastics 
(Updike et al, 1983), antiparasitics (Summers, 1983), veterinary antiamoebics (Jaitely, 1996), 
vitamins (Eichler, 1985), steroids (Jenner et al., 1981), antibiotics (Jain et al., 1995), and 
cardiovascular drugs (Tajerzadeh et al., 2000). 
Several mechanisms were described for the drug release and they include passive diffusion, 
specialized membrane associated carrier transport, phagocytosis of resealed cells by 
macrophages of RES, accumulation of erythrocytes in lymph nodes after subcutaneous 
administration followed by hemolysis to release the drug (Gothoskar, 2004). Possible routes of 
administration for erythrocyte based formulations are intravenous (which is the most common), 
subcutaneous, intraperitoneal, intranasal and oral (Jain et al., 1997). Improved efficacy of 
different drugs administered in this form in animal models have been extensively described and 
published (Gothoskar, 2004). Some of the examples are an improvement of anti-inflammatory 
effect of corticosteroids in experimentally inflamed rats (Jenner, 1981), increase of half-life of 
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isoniaside (Jain et al., 1995), levothyroxine (Field et al., 1989), cytosine arabinoside (Deloach 
et al., 1982), and interleukin 2 (Deloach et al., 1987); prolongation of plasma half-life of 
erythropoietin from 30 minutes to 35 hours in mice (Garin, 1996). 
 
1.6.4.2. Drug targeting 
 
Ideal controlled drug delivery system should be site-specific and target-oriented to show 
maximal possible therapeutic effect with minimum adverse effects (Gothoskar, 2004). 
Erythrocytes and erythrocyte ghosts have a potential to be used as drug carriers and targeting 
tools as well (Gothoskar, 2004). One approach to target organs of mononuclear phagocytic 
system/reticuloendothelial system is surface modification because the changes in the membrane 
are normally recognized by macrophages (Alvarez, 1998) Furthermore, erythrocytes also can be 
used to target organs other than those of RES (Gothoskar, 2004). 
 
1.6.4.3. Targeting RES organs 
 
Phagocytic Kupffer cells in liver and spleen are responsible for the elimination of the damaged 
and altered erythrocytes from circulation (Gothoskar, 2004). Therefore erythrocytes and their 
ghosts can be used to target the liver and spleen after the modification of their membrane 
(Gothoskar, 2004). Different techniques can be employed to modify the surface characteristics 
of erythrocytes: surface modification with antibodies, gluteraldehyde, carbohydrates such as 
sialic acid (Alvarez et al., 1998), sulphhydryl etc. (Gothoskar, 2004). One of the possible options 
is also ex vivo artificial pre-ageing of the cells to increase their uptake by phagocytic cells 
(Bourgeaux et al., 2016). Pre-aging process can be performed by enzymatic, thermal or 
chemical methods (Bourgeaux et al., 2016). The efficiency of neuraminidase enzyme to 
eliminate sialic acid from the surface of the erythrocyte membrane in order to induce cell 
deterioration has been thoroughly examined in one preclinical study (Zocchi et al., 1987). Heat 
treatment (ie, 42 ºC for 90 minutes or 48 ºC for 30 minutes) has also been investigated for the 
pre-aging of cells by energy depletion (Zocchi et al., 1987). Glutaraldexyde as a crosslinker 
reacts extensively with proteins in the erythrocyte membrane and also can be used to target the 
spleen and the liver (Bourgeaux et al., 2016). After the treatment, resulting erythrocytes become 
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extremely rigid which can compromise their use for in vivo applications (Bourgeaux et al., 
2016). Much better option is the usage of  bis(sulfosuccinimydil)suberate because the treatment 
is less aggressive and leads to the crosslinking of specific proteins such as Bend 3. It has been 
confirmed that bis(sulfosuccinimydil)suberate treated erythrocytes are less rigid then 
glutharaldexyde treated cells so they are more suitable for clinical use (Bourgeaux et al., 2016). 
The two main applications of the RES targeting strategy by erythrocytes are: 
1. The delivery of small chemical entities such as antiretroviral nucleoside analogs 
(Magnani et al., 1992), 
2. The encapsulation of antigens for vaccination or tolerance induction (Banz et al., 2010). 
 
1.6.4.4. Targeting the liver 
 
The deficiency of enzymes in the body and consequent metabolic disorders can be treated by 
administering these enzymes in the replacement therapy (Gothoskar, 2004). However, the 
exogenous enzyme therapy is faced with many obstacles such as shorter circulation half-life of 
enzymes, allergic reactions, toxic manifestations etc. (Gothoskar, 2004). These issues could be 
successfully solved by using erythrocytes and their gosts (Gothoskar, 2004). Some examples 
already exist in the literature and they include β-glucosidase, β-glucoronidase, β-galactosidase 
(Jaitely et al., 1996; Eichler, 1986; Deloach et al., 1977).  
Nowadays hepatic tumors represent one of the most prevalent types of cancer (Gothoskar, 
2004). Antineoplastic drugs such as methotrexate (Jaitely et al., 1996), bleomycin (Zimmerman, 
1973), asparginase (Updike et al., 1983) and adriamycin (Al-Achi et al., 1990) have been 
successfully delivered by erythrocytes. 
Resealed erythrocytes selectively accumulate within RES organs which also makes them 
appropriate for the delivery of antiparasitic agents (Gothoskar, 2004). Parasites are known to be  
highly concentrated in the RES organs which opens the possibility to successfully control 
parasitic diseases by this method (Gothoskar, 2004). Proven efficiency is already described in 
animal models for erythrocytes loaded with antimalarial (Summers, 1983), antileishmanial 
(Summers, 1983) and antiamoebic drugs (Jaitely, 1996). 
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1.6.4.5. Targeting organs other than RES 
 
Organs outside the RES can also be targeted by erythrocytes (Gothoskar, 2004). Some of the 
examples include encapsulation of paramagnetic particles or photosensitive material in 
erythrocytes together with the drug, the use of ultrasound waves and antibody attachment to the 
surface of erythrocyte membranes to get specificity of action (Gothoskar, 2004). Study 
performed by Zimmerman et al., described encapsulation of small paramagnetic particles that 
can be localized to a particular location in the body when they are controlled by an external 
magnetic field (Zimmerman et al., 1975). The entrapment of ferrofluids (colloidal suspension of 
magnetite) has been described by Sprandel et al (Sprandel et al., 1980). Antiinflammatory drugs 
diclofenac sodium and ibuprofen were successfully encapsulated in magnetoresponsive 
erythrocytes (Jain et al., 1994). There is also an example of the photosensitized erythrocytes that 
have been developed as phototriggered carrier and delivery system for methotrexate (Flynn et 
al., 1994). Possibility to target cytotoxic T-cells in vitro after the attachment of Thy-1.2 
monoclonal antibody to the surface of erythrocytes has been reported by Chiarantini et al. 
(Chiarantani, 1995). 
 
1.6.4.6. Delivery of antiviral agents 
 
Antiviral agents can also be successfully encapsulated in resealed erythrocytes for the delivery 
and targeting (Ihler, 1983). In most cases, antiviral drugs chemically belong to a group of 
nucleotides or nucleoside analogs, so their transport through the membrane (entrapment and exit 
during the releasing) requires careful consideration (Gothoskar, 2004). Nucleosides can pass 
rapidly through the membrane whereas nucleotides cannot, so they are suitable for the carriers 
with prolonged release profiles (Gothoskar, 2004). Before the release, nucleotides need to be 
converted to purine and pyrimidine bases (Gothoskar, 2004). Examples of the usage of 
erythrocytes as controlled drug delivery systems for antiviral agents are numerous and include 
the delivery of deoxycytidine derivatives (Ihler, 1983), recombinant herpes simplex virus type 1 
(HSV-1) glycoprotein B (Chiarantini et al., 1995), azidothymidine derivatives (Benatti, 1989), 
azathioprene, acyclovir (Magnani, 1998), and fludarabine phosphate (Fraternale et al., 1996). 
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1.6.4.7. Delivery of anti-inflammatory agents 
 
Encapsulation of anti-inflammatory drugs such as glucocorticoids including dexamethasone into 
erythrocytes, is a promising approach for the enhancement of the bioavailability of these poorly-
soluble drugs and selectivity of their delivery to active phagocytes in the RES and other 
components of immune system (Muzykantov, 2010). This concept was extensively studied and 
developed by Magnani et al. and was tested in the human patiens with disease conditions 
associated with inflammation (Magnani et al., 1998, Magnani et al., 2002). In one of the studies 
RBC-loaded with dexamethasone were re-infused in ten patients suffering from chronic 
obstructive pulmonary disease, COPD. The treatment was well tolerated and resulted in a 
sustained elevation of blood DEX level after a single injection (Rossi et al., 2001). In other lung 
disease with a major inflammatory component, cystic fibrosis, re-infusions in the patients of 
autologous RBC-loaded DEX at monthly intervals provided sustained low level of DEX for 28 
days in the blood stream. This treatment was also well tolerated and provided significant 
reduction of inflammatory reactions (Rossi et al., 2004). Furthermore, the similar concept was 
tested in patients with inflammatory bowel disease where three repetitive re-infusions of 
autologous RBC loaded with DEX (every for weeks) were administered. Prolonged increase in 
DEX blood level was achieved and patients were not forced to take previously prescribed poorly 
tolerated steroids anymore. Additionally, achieved remission has been maintained for several 
months (Annese et al., 2005). Encouraging results in previously described studies suggest that 
RBC-mediated delivery of anti-inflammatory agents may be very useful in treatment of acute 
and chronic inflammation (Muzykantov, 2010). 
 
1.6.4.8. Enzyme therapy 
 
In clinical practice enzymes have numerous applications such as replacement therapies to treat 
diseases caused by their deficiency (e. g., Gaucher’s disease, galactosuria), degradation of toxic 
compounds secondary to some kind of poisoning (cyanide, organophosphorus), and as drugs 
(Bird et al., 1983). After administration, enzyme-loaded erythrocytes can release enzymes into 
circulation upon hemolysis (Zimmerman, 1983); act as ‘circulating bioreactors’ in which 
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substrates enter into the cell, interact with enzymes and generate products (Magnani, 1989); or 
accumulate enzymes in RES upon hemolysis for future catalysis (Lewis et al., 1984). 
The first successful clinical trial of the erythrocytes loaded with enzymes was performed in 
1997. with β-glucoserebrosidase for the treatment of Gaucher’s disease (Beutler, 1977). 
Asparaginase, the enzyme that degrades asparagine, an amino acid vital for cell, was entrapped 
into erythrocytes for the treatment of neoplasms in children (Gothoskar, 2004). This treatment is 
proven to prevent remission of pediatric acute lymphocytic leukemia (Tan, 1972) which is 
followed with many reports of improved intensity and duration of action in animals (Updike et 
al., 1983; Alpar et al., 1985) and humans (Jain et al., 1997). RBC-loaded enzyme replacement 
therapy using thymidine phosphorilase has been thoroughly examined in patients with a genetic 
mitochondrial deficiency of this enzyme: treatment improved biochemical readouts but the 
patients’ clinical condition did not improve (Moran et al., 2008). 
Other examples and attempts include urease (Zimmerman et al., 1976), galactose-1-phosphate 
uridyl transferase (Harris, 1977), uricase (Ihler et al., 1975) and acetaldehyde dehydrogenase 
(Tan, 1972). 
 
1.6.4.9. Anti-cancer agents 
 
The main benefits of the loading anti-cancer drugs into carriers are reduction of their toxicity  
and improvement of their delivery to tumors (Muzykantov, 2010). During the last decade 
different technologies such as liposomes, linear polymers and polymer micelles were developed 
as carriers for anti-cancer drugs (Muzykantov, 2010). However, in comparison to these 
conventional concepts, RBC carriers offer an advantage in tumor treatment, for example, by 
providing formulation with prolonged circulation (Muzykantov, 2010). For instance,  
hydrophobic anti-tumor agent dequalinium was encapsulated into mouse RBC which resulted in 
much longer half-life in circulation than PEG-liposomal formulation (5-6 days vs 4 hours) 
(Lizano et al., 2003). 
Anticancer drugs such as antibiotic doxorubicin have been encapsulated into carrier RBC using 
different loading strategies including glutaraldehyde cross-linking of RBC membrane 
(Attaulakhanov et al., 1996). As it was previously mentioned, this procedure improves RBC 
uptake by macrophages and other cells exerting active phagocytosis (Alvarez et al., 1998). As it 
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was expected, doxorubicin- loaded RBC successfully delivered the drug into macrophages in 
culture and concentrated in the liver after intravenous injection in animals including dog (Tonetti 
et al., 1991). This intervention showed good efficiency in treatment of lymphoid tumor in dogs 
without cardiac toxicity which is known to be a common adverse effect of doxorubicin 
(Matherne et al., 1994). Human autologous erythrocytes encapsulated with antracycline 
antibiotic daunorubicin were tested in patients with acute leukemia and showed prolonged drug 
level in plasma and decrease in side effects in comparison to the free drug (Skorokhod et al., 
2004). 
 
Among other carriers, erythrocytes represent a unique, promising and still underdeveloped 
platform for drug delivery (Muzykantov, 2010). After initial burst of interest and research efforts 
for three decades, drug delivery by RBC was overshadowed by artificial carriers offering wider 
range of applications, as well as better control over formulation, storage and utilization of drug 
delivery system than original RBC-based concepts (Muzykantov, 2010). Studies on RBC drug 
delivery systems started with in vitro experiments using isolated RBC and within two decades, 
progressed to extensive animal studies and clinical trials (Muzykantov, 2010). 
 
1.6.5. Novel approaches in product formulation 
 
Some novel approaches and techniques applied in the production of controlled drug delivery 
systems based on erythrocytes and erythrocyte ghosts include layer-by-layer microcapsules 
template on erythrocyte ghost carriers (Shaillender et al., 2011), surface modification (Sternberg 
et al., 2011) and nanoerythrosomes. Schaillender et al. described successful coating of 
encapsulated erythrocyte ghosts with the biocompatible polyelectrolytes, poly-l-arginine 
hydrochloride and dextran sulfate (Figure 5). This study has shown that the release profiles of the 
encapsulated molecules can be controlled over a wide range by changing the number of 
polyelectrolyte layers. Alternative polymeric systems that could be used for the coating include: 
chitosan/alginate, protamine sulfate/dextran sulfate, poly-L lysine/poly-L glutamic acid sodium 
salt, poly-L lysine/dextran sulfate (Shaillender et al., 2011). Aggregation of loaded ghosts can 
be easily followed by using optical microscopy (Shaillender et al., 2011). Since erythrocyte 
ghosts are very soft and fragile, in order to avoid their breakage due to deposition of 
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polyelectrolytes it is important to stabilize them with glutaraldehyde prior to coating 
(Shaillender et al., 2011). Polyelectrolyte layering process can be monitored by measuring ζ-
potential after each coating step (Shaillender et al., 2011). It is well known that the surface of 
erythrocyte ghosts is negatively charged and it converts to a positive value after the deposition of 
the first cationic polyelectrolyte layer (Shaillender et al., 2011). This change in the surface 
charge enables the subsequent deposition of the anionic polyelectrolyte layer (Shaillender et al., 
2011).  
 
 
 
Figure 5. Schematic illustration of the production of layer by layer microsapsules using 
erythrocyte ghosts as template (Shaillender et al., 2011). 
 
Interesting approach in the development of controlled drug delivery systems based on 
erythrocytes is attachment of various molecules such as proteins or peptides to the functional 
groups on the cell surface (Chambers et al., 2004). Even though there are various reversible and 
reversible conjugation approaches, the non-covalent attachment using biotin-avidin bridge is 
considered to be the most biocompatible and successful way of surface modification of 
erythrocytes (Muzykantov, 2010). This technology is especially useful when the drug targeting 
to non-RES sites of the body is desired (Sternberg et al., 2011). One such example is described 
in 2011 by Sternberg et al. In this study albumin-loaded erythrocytes were subsequently surface 
conjugated with insulin and IgG via biotin–streptavidin. Insulin-conjugated erythrocytes were 
observed to attach and to be internalized by cultured endothelial cells. On the other hand, uptake 
was not observed for carrier-RBCs non-specifically modified with IgG (Sternberg et al., 2011). 
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Nanoerythrosomes, engineered derivative or erythrocytes with an average diameter of 100 nm, 
are being prepared by hypotonic lysis of erythrocytes followed by extrusion usually through 
polycarbonate membranes (Gupta et al., 2014). Their physicochemical properties (Deák et al., 
2015; Kuo et al, 2016) as well as their potential application (Gupta et al., 2014) are extensively 
described in the literature. 
One of the first successful encapsulations of the drug in nanoerythrosomes was performed in 
1994. by Lejeune et al. using daunorubicin as a model compound (Lejeune et al., 1994). Gupta 
et al. gave detail insight in preparation and characterization of nano-engineered erythrocyte 
ghosts as inhalational carriers for delivery of fasudil (Gupta et al., 2014) (Figure 6). Fasudil, a 
potent Rho kinase inhibitor and vasodilator, is used in the inhalation therapy for pulmonary 
arterial hypertension (Gupta et al., 2014). However, fasudil has very short half-life which can be 
extended by encapsulating in liposomes (Gupta et al., 2014). Alternative option could be 
nanoerythrosomes - insufficiently examined cell based capsules with semipermeable membrane 
(Gupta et al., 2014). 
Nanoerythrosomes were prepared by reducing the size of erythrocyte ghosts containing fasudil 
(Gupta et al., 2014). In this study, three different size reduction techniques were used to produce 
nanosized erythrosomes: 1. bath sonication, 2. probe sonication, 3. extrusion (Gupta et al., 
2014). Sizing with sonication gave polydispersed particles and significantly decreased 
entrapment efficiency (Gupta et al., 2014). However extrusion performed with polycarbonate 
membranes of different sizes had minimal effect on entrapment efficiency indicating little or no 
disruption of cells (Gupta et al., 2014). This study has shown that produced nanoerythrosomes 
can be easily taken up by rat pulmonary arterial smooth muscle (PASM) cells, can extend the 
half-life of fasudil and appear to be safe for intratracheal delivery (Gupta et al., 2014). 
Additionally, the final formulation had satisfying entrapment efficiency, in vitro release and 
stability profiles (Gupta et al., 2014). 
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Figure 6. Schematic representation for preparation of nanoerythrosomes from rat whole blood 
using hypotonic lysis followed by extrusion method. (Gupta et al., 2004). 
 
Recently Agnihotri et al. developed artesunate-loaded nanoerythrosomes that offered improved 
pharmacokinetic profile with assurance of increased therapeutic efficacy (Agnihotri et al., 2015). 
According to the current opinion, nanoerythrosomes represent “golden eggs in novel drug 
delivery systems” taking into account their tremendous potential (Nangare et al., 2016). 
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EXPERIMENTAL PART 
 
1. Controlled drug delivery system based on mesoporous 
silica 
1.1. Ordered Mesoporous Silica 
Ordered mesoporous silica (OMS) material was synthesized according to the synthesis procedure 
described by Jammaer et al. (Jammaer et al., 2009). Briefly, a citric acid buffered solution 
Pluronic® P123 (BASF, Ludwigshaven, Germany) was prepared overnight. To this surfactant 
solution, a sodium silicate (NaSi) solution was added and the mixture was stirred. The final 
synthesis mixture was kept nonstirred 24 h at room temperature followed by 48 h at 75 ºC. The 
material is then filtered, washed with deionized water, and dried. Finally the OMS material was 
calcined under ambient conditions at 550 ºC. 
1.2. Fenofibrate Loading Procedure 
Loading of fenofibrate into the OMS material was carried out with an automated granulator 
(Mipro 900, ProCepT, Zelzate, Belgium). Pure API (8.19 g) was dissolved in 80 mL of 
dichlormethane. The API solution was filtered through a 0.45 µm PTFE filter and added to the 
OMS in the granulator bowl in two steps using an atomization nozzle. Each dosing step was 
followed by a drying step (30°C) of 45 minutes. The loading of the OMS was 29% (w/w) of API. 
The loaded material was further dried for 3 days in circulating air oven at 25°C to remove 
residual dichloromethane. 
1.3. Drug Load Quantification 
In order to determine the amount of fenofibrate loaded into the OMS, approximately 7.5 mg of 
the loaded silica was weighed in a volumetric flask of 25.0 mL. Dimethyl sulfoxide (5.0 mL) 
was added and then filled up with acetonitrile. The suspension was sonicated for 30 minutes in a 
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Branson 8200 ultra-sonic bath, filtered afterwards using a 0.45 µm PTFE membrane filter (VWR 
International, USA) and analyzed with high performance liquid chromatography (HPLC) with 
UV detection. 
1.4. Dosage Form 
The fenofibrate loaded OMS was blended with silicified microcrystalline cellulose (Prosolv® HD 
90, JRS Pharma) and croscarmellose sodium (AcDiSol®, FMC Biopolymer, USA), see Table 6. 
Blending was performed in the MiPro Granulator. Two capsule formulations (eq. 33.5 mg 
fenofibrate and eq. 16.75 mg fenofibrate) were compared to the commercially available forms 
Lipanthyl® and Tricor®.  All formulations were evaluated in vitro prior to the in vivo dog and 
human study. 
Table 6. Compositions of Fenofibrate-Loaded OMS Capsules. 
Dosage Form Formac OMS Capsules 
 Eq. 33.5 mg (%) Eq. 16.75 mg (%) 
Fenofibrate loaded OMS 57.76 50.20 
Acetone*   
Sodium crosscaramelose 10.00 10.00 
Silicified microcrystalline cellulose 32.34 39.80 
*Not present in the final formulation. 
 
1.5. In Vitro Dissolution Study 
To study the release of fenofibrate out of the OMS carrier, the loaded formulations were 
suspended in 900mL 0.1N HCl (VWR Prolabo, Belgium) + 0.1% Tween 80 (Acros Organics, 
Belgium). Dissolutions were performed using a Hanson Vision® Elite 8 dissolution apparatus 
(USP II – Padlle). The paddle speed was set at 50 rpm. The experiment was performed at 37 °C. 
Samples of 1.0 mL were taken at 5, 10, 15, 30, 60 and 120 minutes and filtered over a 0.45µm 
PTFE membrane filter (VWR International, USA). The volume withdrawn is replaced by the 
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same amount of fresh medium. The samples were diluted and analyzed using HPLC with UV 
detection (see below). 
 
1.6. High Performance Liquid Chromatography (HPLC) 
Measurements of the assay and in vitro dissolution samples were performed using an isocratic 
HPLC method. The HPLC system was a VWR Hitachi Elite LaChrom with a L-2200 UV 
detector set at 287 nm. The analytical column used is a Lichrospher 60 (125mm – 4,6mm; 5µm). 
A mobile phase made up of 25mM ammonium acetate buffer pH 3.5 / acetonitrile (30:70; v:v) 
with a flow rate of 1mL/min was used. The column temperature was set at 30°C and the injection 
volume was 20µL. 
 
1.7. Preclinical trial in beagle dogs 
 
1.7.1. Analysis of plasma samples 
 
A bioanalytical method was used for the quantification of fenofibrate and fenofibric acid in the 
dog oxalate plasma in the range of 0.02 – 4.00 ng/mL and of 10.00 - 2000.00 ng/mL, 
respectively. The dog plasma samples were thawed at room temperature, homogenized and 
centrifuged. 50 µL of supernatant was mixed with 450 µL of a solution of the internal standard 
(fenofibrate-d6 (0.05 ng/mL) and fenofibric acid-d6 (1250 ng/mL)) in acetonitrile and 
subsequently centrifuged at high speed. For the analysis of fenofibric acid, 50 µL of the elution 
was then transferred to a 96-well plate, mixed with acetonitrile/water (90:10 v/v), shaken for 5 
minutes and then 6.0 µL was injected into UPLC-MSMS system. For the analysis of fenofibrate, 
the rest of the elution was evaporated at 50 ºC, dissolved in 50 µL acetonitrile/water (90:10 v/v), 
shaken for 5 minutes and then 10.0 µL was injected into UPLC-MSMS system. The targeted 
compounds were analyzed on Acquity UPLC BEH C18 column (50*2.1mm, dp = 1.7µm), 
applying acetonitrile:water:ammonium acetate (10:85:5, v/v/v) and (90:5:5, v/v/v) in the linear 
gradient mode as mobile phase. Quantitation method was based on peak area ratio and the 
response versus concentration data were fitted using quadratic regression with 1/x2 weighting. 
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1.7.2. Pharmacokinetic analysis 
 
Pharmacokinetic (PK) parameters were evaluated after single oral administration in 4 male 
Beagle dogs (31 – 36 months old, body weight range 10.8 – 11.8 kg; Marshall BioResources, 
Italy).  
From all animals approximately 4 mL blood samples were taken from the jugular vein using 
vacutainers and potassium oxalate/sodium fluoride (Greiner Bio-One, Bad Haller, Austria) as 
anticoagulant. Blood was sampled at predose and 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h after dosing. 
Within 30 minutes after sampling, blood was centrifuged at 5 ºC. Immediately after 
centrifugation, plasma was stored in labeled polypropylene tubes at – 75 ºC prior to analysis. 
This study protocol was reviewed and agreed by the Animal Welfare Officer and the ethical 
Committee of NOTOX (00 – 34) as required by the Dutch Act on Animal Experimentation 
(February 1997). The animals were treated in accordance with the Directive 2010/63/EU.  
The study procedures were based on the following guidelines, recommendations and 
requirements:  
- Workshop/Conference Report – Quantitative Bioanalytical Methods Validation and 
Implementation: Best practices for Chromatographic and Ligand Binding Assays. C. T. 
Viswanathan, et al. The AAPS Journal, 9, 2007, E30 – E42. 
- Guidance for industry: Bioanalytical Method Validation. US Department of Health and 
Human Services, Food and Drug Administration, Center for Drug Evaluation and 
Research (CDER) and Center for Veterinary Medicine (CVM). May 2001. 
All PK parameters were calculated from the curves constructed from individual animals, using 
the WinnonLin 5.2 program. Noncompartmental analysis was applied using the extravascular 
model. The lower limit of quantification (LLOQ) of fenofibrate was 0.020 ng/mL and for 
fenofibrate acid the LLOQ was 10.00 ng/mL. All values below the LLOQ after Cmax were 
excluded from the pharmacokinetic evaluation. If a value was below the LLOQ prior to Cmax, 
than this value was set to 0 ng/mL. In case several intermediate not quantifiable concentrations 
were present, all not quantifiable concentrations and all following time points were excluded 
from the kinetic evaluation. In case one intermediate not quantifiable concentration was present, 
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this time point was excluded was excluded from the kinetic evaluation. Nominal sampling times 
were used (deviations were less than 20 %). 
The following pharmacokinetic parameters were calculated: 
- Cmax – maximum observed plasma concentration. 
- Clast – last measurable plasma concentration. 
- tmax – time point at which maximum plasma concentration was reached, assessed directly 
from the data. 
- tlast – time point of last measurable plasma concentration. 
- AUClast  – area under the plasma concentration-time curve from time of administration 
until the last measurable plasma concentration (tlast), calculated using the linear 
trapezoidal rule (for both parent and metabolite). 
- AUC∞ - area under the curve after a single dose from time of administration until infinity, 
calculated as AUClast  + Clast/λz where Clast is the last measurable concentration. If the data 
set did not allow extrapolation to infinity, then the AUC up to the last measurable time 
point was calculated. Extrapolations of more than 15% of the total AUC were reported as 
approximation. 
- λz – elimination rate constant, determined by linear regression of the terminal points of 
the In-linear concentration-time curve. 
- t1/2 – elimination half-life, calculated as ln(2)/λz. The following requirements had to be 
met for an acceptable calculation of t1/2: 
1. at least three time points had to be available to be used in the calculation 
2. correlation coefficient (r2) was at least 0.9 
3. span of time points used in t1/2 was at least twice the calculated value of t1/2 
Values that did not meet these criteria were reported as approximations. Cmax and AUC values 
were also normalized to a dose of 1 mg/kg.  
A descriptive statistical analysis was performed (mean values and standard deviations). A one-
way ANOVA was performed for the dose-normalized values of Cmax and area under the curve 
(AUClast) for each compound to determine a possible statistical difference between the various 
compounds. 
 
 
43 
 
1.8. Stability program 
 
OMS capsules containing fenofibrate (33.5 mg) were stored at 25 ºC/60% relative humidity (RH) 
and 40 ºC/75% RH in both open and closed conditions. After 1, 2 and 6 months of storage, the 
formulation was evaluated for in vitro release (Hanson Vision® Elite 8) and the absence of 
crystallinity (DSC, Mettler-Toledo DSC 822e; Mettler-Toledo, Zaventem, Belgium). For the 
purpose of the thermal analysis, about 3 - 4 mg of the sample was placed in DSC aluminum pans 
and heated from -30 to 150 oC with constant heating rate of 10 oC/min. 
 
1.9. Clinical trial 
 
1.9.1. Subjects 
 
The clinical trial was conducted at SGS Life Science Services (Clinical Pharmacology Unit 
Antwerp, Belgium). Details of the subject population are provided in Table 7. 
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Table 7. Demographic data by treatment sequence (safety population). 
 
Parameter Sequence AB 
N=6 
Sequence BA 
N=6 
All subjects 
N=12 
Age, years 
Median (range) 
 
49 (40-55) 
 
43 (21-49) 
 
46.5 (21-55) 
Height, cm 
Median (range) 
 
178 (168-192) 
 
180 (175-192) 
 
178 (168-192) 
Weight, kg 
Median (range) 
 
80.5 (73-101) 
 
80 (66-90) 
 
80 (66-101) 
BMI, kg/m2 
Median (range) 
 
25.9 (24.4-27.4) 
 
24.5 (20.8-27.8) 
 
25.2 (20.8-27.8) 
Sex, n (%) 
Male 
 
6 (100) 
 
6 (100) 
 
12 (100) 
Race, n (%) 
Caucasian 
 
6 (100) 
 
6 (100) 
 
12 (100) 
N = number of subjects; n = number of subjects with that observation; Treatment A: single oral dose of 
33.5 mg Fenofibrate-OMS; Treatment B: single oral dose of 67 mg Lipanthyl®. 
 
The subjects were in a good health as assessed by detailed medical history, physical examination, 
12-lead electrocardiogram (ECG), clinical laboratory tests and urinary drug screen. All subjects 
were non-smokers. The time span between the screening visit and the last follow-up visit was at 
most 6 weeks. Subjects were to discontinue all medications, except occasional paracetamol 
(maximum dose of 2 g/day and maximum of 10 g/2 weeks), at least 2 weeks prior to the first 
study drug administration. In addition, subjects were to agree not to use any medications during 
the course of the study. Subjects were not to take any alcohol and grapefruit-containing foods 
from 48 hours before to 96 hours after each study drug administration or xanthine-containing 
beverages and food from 12 hours before to 96 hours after each study drug administration. 
Subjects with a history of hypersensitivity to fenofibrate or a significant allergic reaction to any 
drug, an immunosuppressive condition, malignancy within the past 5 years, significant blood 
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loss within 8 weeks prior to study start, diseases of the gastrointestinal tract, liver, kidneys or any 
other conditions known to interfere with the absorption, distribution, metabolism or elimination 
of drugs were excluded from the study. Individuals with active drug or alcohol abuse within 2 
years prior to the initial study drug administration or consumption of large quantities of coffee or 
tea were also excluded.  
All subjects were Caucasian males. The subjects’ median (range) age was 46.5 (21-55) years. 
Their median (range) BMI was 25.20 (20.8-27.8) kg/m². There were no relevant differences in 
demographic data between the treatment sequences. Serology screening tests for hepatitis B and 
C and HIV, urine drug screening, and alcohol breath tests at screening were negative for all 
subjects. A wide range of medical history was reported across the subjects; none of these were 
thought to have influenced the course of the study. Concomitant diseases were reported in 
1 subject (16.7%) in each treatment sequence. Both were Gilbert’s Disease. Previous medication 
was reported in none of the subjects and 1 subject (8.3%) was administered Ditemer (tetanus, 
diphtheria vaccine) in Dosing Period 2 due to a head injury reported as an AE in Dosing Period 
1.  
In each of the two dosing periods, the subjects were admitted to the clinical centre on Day -1 and 
remained hospitalized until approximately 24 hours after dosing (Day 2). Thereafter, subjects 
were to return to the clinical centre on Days 2 (evening), 3, 4, and 5 for post-dose bioanalysis 
blood sampling. A follow-up visit was planned between 5 to 7 days after the last intake of study 
drug. The two dosing periods were separated by a 7-day wash-out period. All study drug intakes 
occurred under the supervision of the investigator or his designee. The study drugs were 
administered between 8 and 10 a.m. In each dosing period, the subjects received an evening meal 
on Day -1, at least 9 hours before intake of study drug, and a lunch, snack, and evening meal on 
Day 1. During confinement at the clinical centre, no food intake other than the standard meals 
was authorized. On the days of blood sampling for bioanalysis water intake was prohibited from 
2 hours pre-dose until 2 hours post-dose, with the exception of the water intake of 200 mL with 
dosing. Water was available ad libitum from 2 hours post-dose onwards. Subjects who 
discontinued the study prior to completion of the scheduled study procedures for reasons such as 
adverse events (AE) or withdrawal of consent were invited for a follow-up visit 5 to 7 days after 
the last study drug intake. In case of an AE, the appropriate follow-up procedure was applied. 
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1.9.2. Safety monitoring 
 
In each dosing period, subjects underwent a physical examination, an assessment of vital signs 
and a 12-lead ECG recording on Day 1 pre-dose. Blood and urine sampling for clinical 
laboratory tests (haematology, serum biochemistry and urinalysis) were performed in fasting 
conditions. All assessments were performed within 2 hours pre-dose. Subjects were discharged 
from the clinical centre upon agreement of the investigator on Day 2, after safety assessment 
(blood and urine samples for clinical laboratory tests, ECG, vital signs) and the last blood 
sampling for bioanalysis. The subjects returned to the clinical centre 5 to 7 days after the last 
dose administration for the follow-up visit for a physical examination and vital signs (HR, SBP, 
DBP, oral body temperature) assessment. Blood and urine samples for clinical laboratory tests 
were taken in fasting conditions. Any adverse or unusual event occurring from the study 
inclusion date to the last subject’s visit, whether it is observed by the investigator, his staff or the 
subject, was recorded.  
 
1.9.3. Blood sampling 
 
Blood samples for the determination of fenofibric acid in plasma were taken at pre-dose and at 
30 minutes and 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 24 hours (Day 2 morning), 36 hours (Day 2 
evening), 48 hours (Day 3), 72 hours (Day 4) and 96 hours (Day 5) post-dose in each dosing 
period. Samples on Days 1 and 2 (morning) were taken during the subject’s stay in the clinic and 
the subjects needed to return to the clinic for blood sampling on Days 2 (evening), 3, 4, and 5. 
Each sample (4 mL) was taken by venipuncture (or indwelling cannula) in the arm and collected 
in vacuum tubes containing lithium heparin (Venoject green top or equivalent). Samples were 
chilled immediately in an ice bath and centrifuged (at 4-8°C for 10 minutes at ca. 1500 g) within 
30 minutes after blood collection. The plasma obtained was transferred into two polypropylene 
tubes (around 500 µL of plasma per tube) and stored at -20°C after appropriate labelling.  
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One aliquot was shipped on dry ice to the analytical laboratory where the plasma was stored at -
20°C pending analysis. The remaining sample was shipped separately and was stored for back-
up analysis.  
 
1.9.4. Analysis of plasma samples 
 
An analytical method for the determination of fenofibric acid in lithium heparinized human 
plasma was developed and validated by SGS Life Science Services, Wavre, Belgium. The frozen 
plasma samples were thawed at room temperature, homogenized and centrifuged. 20 µL of the 
supernatant was mixed with 20 µL of a solution of the internal standard (fenofibric acid d6) and 
70 µL of acetonitrile and subsequently centrifuged at high speed. 20 µL of the supernatant was 
then transferred to a 96-well plate, mixed with 80 µL of a 0.05% v/v formic acid solution and 
centrifuged. 10 µL of the supernatant layer was then analyzed by LC/MS-MS. The LC/MS-MS 
system consisted of an Agilent 1100 series HPLC system (Agilent, Brussels, Belgium) equipped 
with a CTC HTS PAL autosampler (Cohesive Technologies, Milton Keynes, U.K.) and 
connected with a API 4000 mass spectrometer in the negative ion mode (AB Sciex, Nieuwerkerk 
a/d Ijssel, The Netherlands). The analytical column used was a Chromolith Fastgradient, RP-
C18, 50 x 2.0 mm I.D. (VWR, Leuven, Belgium). A gradient program was followed with two 
mixtures of acetonitrile and a 0.05 % v/v aqueous solution of formic acid: 10/90 v/v and 90/10 
v/v.   
The analytical method was validated with a lower limit of quantification (LLOQ) of 10 ng/mL 
and an upper limit of quantification (ULOQ) of 5000 ng/mL. The response versus concentration 
data were fitted with a first order polynomial with 1/C2 weighting. The within and between-
series precision,  expressed as the coefficient of variation (CV) and accuracy expressed as the 
relative error of measurement (RE), were both below 20 % at the LLOQ and below 15% at the 
higher concentrations which is in accordance with the preset criteria. The average carry-over was 
less than 20% for the analyte and less than 5% for the internal standard and the normalized 
matrix factor was within the acceptance criteria. The average extraction recovery was consistent 
over the investigated range and the 10-fold dilution of the samples did not affect precision or 
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accuracy of the analytical results. The stability of fenofibric acid was assessed for various 
conditions of use and storage of the plasma samples and extracts.  
 
1.9.5. Pharmacokinetic analysis 
 
The pharmacokinetic analysis of the bioanalytical data was performed by SGS Life Science 
Services, Wavre, Belgium using the SAS version 9.1.3. WinNonlin version 5.2. The following 
pharmacokinetic parameters were determined from the individual plasma concentration vs time 
profiles:  
Cmax Maximum observed plasma concentration 
Cmax/dose Cmax normalized to unit dose (1 mg) 
tmax Time of occurrence of Cmax 
AUC Area under the plasma concentration versus time curve from 
time zero to the last sampling time at which concentrations 
were at or above the limit of quantification [AUC0-t], up to 
24 hours post-dose [AUC0-24h], or up to 48 hours post-dose 
[AUC0-48h] calculated by the linear trapezoidal rule 
AUC0-t/dose  AUC0-t normalized to unit dose (1 mg) 
AUC0-24h/dose  AUC0-24h normalized to unit dose (1 mg) 
AUC0-48h/dose  AUC0-48h normalized to unit dose (1 mg) 
AUC0- Area under the plasma concentration versus time curve from 
time zero to infinity, calculated from AUC0-t + (Ct/z), where 
Ct is the last observed quantifiable concentration 
AUC0-/dose AUC0- normalized to unit dose (1 mg) 
λz  Apparent terminal elimination rate constant 
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t1/2,λz Apparent terminal elimination half-life, calculated from 
(ln 2)/z 
Calculation of pharmacokinetic parameters was performed using the actual sample collection 
times. If the actual sampling time of an individual sample was greater than 20% different from 
the scheduled sampling time, the individual concentration was excluded from the descriptive 
statistics for the concentration-time table and mean concentration-time graphs. If the percentage 
of the AUC extrapolated exceeded 20% of the total AUC0-∞, the AUC0-∞ was excluded from any 
statistical evaluation. λz was to be calculated using at least 3 data-points not including the peak 
plasma concentration (Cmax). The acceptable adjusted R
2 value was ≥ 0.85. If this condition was 
not fulfilled, then the related parameters were not tabulated. 
 
1.9.6. Statistical methods  
 
Descriptive statistics applied in this study included the number of data (N), arithmetic mean, 
standard deviation (SD), coefficient of variation (CV), standard error (SE), % confidence interval 
(CI) of the mean, median, minimum and maximum. For continuous parameters, descriptive 
statistics were presented when the number of non-missing data points was greater or equal to 2. 
All statistical inferential tests were interpreted at the 5% two-sided significance level. 
Strict statistical criteria were not used to determine the sample size for this study. The number of 
subjects included in this study should give reasonable precision around the estimates derived for 
the pharmacokinetic analysis. Allocation of each subject to one of the 2 treatment sequences (AB 
and BA) was described in a randomization list prepared by the Biostatistics Department of SGS 
Life Science Services using SAS software (SAS Inc., Cary, NC, USA). 
The two-period, two-sequence cross-over design with phases of treatment separated by an 
adequate wash-out period was chosen in such a manner that any formulation effect could be 
distinguished from other effects. The cross-over design provided a within-subject comparison for 
the treatments. 
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Comparison between treatments was assessed on ln-transformed parameters (Cmax/dose, 
AUC0-t/dose, AUC0-24h/dose, AUC0-48h/dose, AUC0-/dose, t1/2,λz) by means of a mixed-effect 
analysis of variance (ANOVA) with treatment, sequence, and period as fixed effects, and subject 
(nested within sequence) as random effect. Point estimates were calculated as the geometric 
mean of the individual ratios of each parameter for the test treatment (33.5 mg Fenofibrate-
OMS) relative to the reference treatment (67 mg Lipanthyl®) and expressed as a percentage. The 
90% CIs of the point estimates (PE) were calculated using the mean square error of the ANOVA. 
As tmax is a discrete variable dependent on selected blood sampling times, the same comparison 
(33.5 mg Fenofibrate-OMS versus 67 mg Lipanthyl®) was assessed using a non-parametric test 
(Koch procedure). The 90% CI was calculated by the Hodges-Lehmann method. 
 
1.9.7. Regulatory compliance 
This study was conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki and the International Conference on Harmonization (ICH) Note for 
Guidance on Good Clinical Practice (GCP) (CPMP/ICH/135/95) and with applicable local 
requirements. Prior to the performance of any study-specific procedure, written informed consent 
was obtained from each subject. The final clinical trial protocol (CTP) as well as the informed 
consent and other information that required pre-approval were reviewed and approved by an 
Independent Ethics Committee (IEC; Commissie voor Medische Ethiek – Ziekenhuisnetwerk 
Antwerpen – ZNA/OCMW, Antwerp, Belgium) according to specifications outlined in the 
applicable regulations. 
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2. Controlled drug delivery system based on erythrocyte 
ghosts 
2.1. Erythrocyte samples 
 
Porcine slaughterhouse blood and human outdated blood were used as a starting biological 
material for erythrocytes isolation. Porcine blood was from the slaughterhouse “PKB Imes” in 
Belgrade, Serbia. Transport and treatment of the Swedish Landrace swine in the slaughterhouse 
was in obedience to the National Regulation on Animal Welfare, and performed in compliance 
with institutional animal care and use policies. The porcine blood collection and transport was 
done according to the protocol described in Kostic et al. (Kostic et al., 2015). The human 
erythrocytes concentrates were from Institute for Transfusiology and Hemobiology, Military 
Medical Academy, Belgrade, Serbia. The blood was from healthy blood donors. The 
erythrocytes were enriched by the standard procedure and preserved in SAGM solution (each 
100 mL contains 0.900 g dextrose monohydrate, 0.877 g sodium chloride, 0.0169 g adenine, and 
0.525 g mannitol) for 42 days at 4 °C. The outdated cell packs were anonymized prior to 
distribution, and the link to the donor was broken. If were not used for the research, these cell 
packs would be discarded after the expiration date. Preparation of packed porcine and human 
erythrocytes suspensions were performed as described in Kostić et al. (Kostic et al., 2015).  
 
2.2.  Erythrocyte ghosts’ preparation and encapsulation 
(loading) with SD  
 
In order to prepare erythrocyte ghosts, porcine and human erythrocytes were undertaken to the 
osmosis based process-gradual hypotonic hemolysis (Kostic et al., 2015). 
According to known literature data regarding the different osmotic properties of porcine and 
human erythrocytes (Kostic et al., 2015.; Doucet et al., 2004) hypotonic 35 mM sodium 
phosphate/NaCl buffer for porcine and 5 mM sodium phosphate buffer for human erythrocytes 
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were introduced gradually for 30 min with flow rate 150 mL/h in 50 mL of packed erythrocytes 
in PBS (with hematocrit value of 0.5) and continuously mixed. After the hemolysis the 
erythrocyte ghosts were isolated, washed three times in hypotonic solution used in gradual 
hemolysis process and finally in isotonic PBS solution. 
For the purposes of encapsulation, gradual hypotonic hemolysis process was performed as 
previously described but in the presence of SD in concentration of 120 mg/L. After the 
hemolysis, the erythrocyte ghosts were precipitated (40 min centrifugation at 3220xg, at 4°C), 
supernatant containing hemoglobin was discarded and erythrocyte ghosts were washed four 
times in the buffer solution used for the gradual hypotonic hemolysis process. Densely packed 
erythrocyte ghosts in the volume of 2 mL were incubated with 8 mL of PBS containing 120 
mg/L SD, 90 minutes at 37 °C. After the incubation, samples were stored at 4 °C over the night. 
The next day, erythrocyte ghosts were precipitated by 40 min centrifugation at 3220xg. The 
erythrocyte ghosts in the volume of 220 µL were dispersed in test tubes containing 1780 µL of 
hypertonic 2XPBS solution with SD (120 mg/L) and 0.01% glutaraldehyde and then incubated 
for 30 minutes at 37 °C in test tubes. The encapsulated ghosts were precipitated by 5 min 
centrifugation at 10000xg and washed out twice in PBS solution without SD, to remove non-
encapsulated SD. 
 
2.3. Sample preparation for qualitative and quantitative analysis 
of encapsulated (loaded) SD 
 
From the final suspension of encapsulated erythrocyte ghosts, 100 µL was taken and dispersed in 
2 mL of distilled water and mixed with 2 mL of methanol. Test tubes were stored at the room 
temperature for 30 minutes and then centrifuged 15 minutes at 14000xg. Obtained supernatants 
were filtered through the filters with pore size 0.2 µm into the vials and used for the below 
described HPLC analysis. 
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2.4. Qualitative and quantitative analysis of encapsulated SD 
  
SD is quantified in samples of loaded ghosts using an UHPLC/DAD/-HESI-MS/MS method. 
Separation, identification, and quantification of diclofenac was performed using Dionex Ultimate 
3000 UHPLC system (ThermoFisher Scientific, Bremen, Germany) coupled to diode array 
detector (DAD), and connected to TSQ Quantum Access Max triple-quadrupole mass 
spectrometer (ThermoFisher Scientific, Basel, Switzerland). Elution was performed at 30 ºC on 
Hypersil gold C18 column (50 × 2.1 mm) with 1.9 μm particle size (ThermoFisher Scientific, 
USA). The mobile phase consisted of (A) water + 0.1% formic acid, and (B) acetonitrile (MS 
grade, Fisher Scientific UK, Leics, UK), which were applied in the gradient elution previously 
described in Kostić et al. (Kostic et al., 2015) The flow rate was set to 0.4 mL min-1  and the 
detection wavelengths to 230 and 280 nm. The injection volume was 10 μL. All the analyses 
were performed in triplicate. 
Mass spectrometer was equipped with an heated electrospray ionization (HESI) source, and was 
used with vaporizer temperature kept at 350 °C, and ion source settings as follows: spray voltage 
3500 V, sheet gas (N2) pressure 28 AU, ion sweep gas pressure 0 AU and auxiliary gas (N2) 
pressure at 4 AU, capillary temperature at 270 °C, skimmer offset 0 V. Mass spectrometry data 
were acquired in negative mode, in m/z range from 100 to 1000. Collision-induced 
fragmentation experiments, including product ion scanning (PIS) and selected reaction 
monitoring (SRM), were performed using argon as the collision gas, and collision energy (cE) 
was set to 20 eV. SRM experiment for quantitative analysis was performed by using two MS2 
fragments, which were previously defined as dominant in PIS experiments. Quantification of SD 
was based on the calibration curve of pure compound. Total amount of SD in each sample was 
evaluated by the calculation of peak areas, and is expressed as ng ml-1. Chromeleon Xpress 
softver (Thermo Fisher Scientific, Bremen, Germany) was used for used for the data acquisition 
and method/run control. 
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2.5. Loading parameters 
 
Two parameters were determined and were used for evaluation of loading efficiency of the 
method (Hamidi et al., 2011): 
1. Loaded amount: The amount of SD encapsulated in 0.1 mL of the final packed 
erythrocyte ghosts. 
2. Encapsulation efficiency: The percent ratio of loaded amount of SD to amount added per 
0.1 mL during the encapsulation process. 
 
2.6. SD effect on gradual hypotonic hemolysis 
 
In order to investigate the effect of SD on gradual hypotonic hemolysis process, the 1 mL 
aliquots of the erythrocyte suspension were sampled at the beginning of the process, and in 1 
minute time interval for the first 5 minutes of hemolysis, in 3 minutes time intervals for the next 
15 minutes, and in the time intervals of 5 minutes by the end of the experiment. 
As a control, the same test was performed in gradual hypotonic hemolysis processes without SD. 
The samples were centrifuged at 15 000 g for 20 minutes, and hemoglobin and potassium content 
in the supernatants were determined by cyanmethemoglobin method (Van Asendelft et al., 1984) 
and ion selective electrode, respectively. The percent of hemoglobin and potassium release were 
determined in reference to the total amount released at the end of gradual hypotonic hemolysis 
(100% hemolysis). 
 
2.7. Particle size analysis 
 
Particle size and size distribution analysis of starting erythrocytes and resulting empty and SD 
loaded ghosts was performed by using laser-based particle size analyser Mastersizer Hydro 
2000S (Malvern Instruments Ltd, U.K.). For this purpose, the samples were analysed while 
suspended in isotonic PBS in a suitable concentration, according to instrument operation 
conditions. 
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2.8. FT-IR analysis 
 
The FT-IR spectra of SD, lyophilized empty and SD loaded erythrocyte membranes were 
obtained by means of Fourier transform infrared spectroscopy (FTIR spectrometer Bomem MB, 
series Hartmann & Braun) with a resolution of 2 cm-1, by the KBr method. The spectra were 
taken in the wavelength region 4000–400 cm-1 at room temperature.  
 
2.9. Zeta potential determination 
 
Zeta potential determination of starting erythrocytes, empty and encapsulated human and porcine 
erythrocyte ghosts were performed using a Zetasizer Nano ZS (Malvern Instruments, U.K.) 
apparatus operating at λ= 633 nm produced by an He–Ne laser at scattering angle 173° at 25± 0.1 
°C. The calculation of zeta potential values of diluted samples (according to the manufacturer 
instructions) were done by computer software from electrophoretic mobility using the 
Smoluchowski equation: ξ = μη/ε, where ξ is the zeta potential, μ is the mobility, η is the 
viscosity of the solution, and ε is the dielectric constant of the solvent. The results represent the 
average value of three consecutive measurements for each sample. 
 
2.10. Atomic force microscopy 
 
In order to perform morphological examination by AFM, the samples were fixed onto the surface 
of a coverslip by incubation with 2.5% glutaraldehyde in PBS for 1 hour. The samples were 
further fixed with osmium tetroxide (0.1 %) in PBS for 1 hour. Osmium tetroxide was removed 
by washing twice in PBS. The drying of samples was performed with an increasing 
concentrations of ethanol (10%, 30%, 50%, 70%, 95% and 100%) and finally in acetone. 
Topographic AFM measurements were performed in the semi-contact mode under ambient 
conditions using the NTEGRA Prima system from NT-MDT (NT-MDT Co. Moscow, Russia). 
NSG01 probes from NT-MDT with a typical tip curvature radius of about 6 nm and a typical 
force constant of 5 N/m were used. Topographic images were processed using the instrument-
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equipped software by the plane subtraction or by the fitting with the first order lines. For the 
calculation of the root-mean-square (RMS) of the surface roughness, only cell surfaces were 
selected from AFM images and then RMS was directly generated by the instrument software, 
using a total of 10 cell measurements for each ghost preparations. 
 
2.11. Drug release 
 
To examine the release behaviour of SD from porcine and outdated human erythrocyte ghosts, 
100 µL of densely packed suspension in each test tube was diluted to 1 mL by adding 900 µL of 
PBS solution. The tubes (n=5) were mixed on the orbital shaker at 240 rpm and incubated at 37 
ºC. After 1, 2, 24, 48 and 96 h one of the samples was harvested and after centrifuging at 10 000 
g for 10 min, 100 µL of the supernatant was used for the HPLC analysis. These experiments 
were carried out in triplicate and the percent of SD release was determined in reference to a 
completely lysed sample (100% release). Due to possible microbial contamination drug releasing 
test was not performed longer than 4 days. 
 
2.12. Statistical analysis 
 
Experimental results were mean ± SD of at least three measurements. Statistical analysis of the 
data regarding antihemolytic effect of SD, number based diameter distribution and ζ-potential 
was performed by Student t test with the Origin 9.0 Statistical Analysis Software. The values p < 
0.05 were regarded as significant. 
 
2.13. Two photon excitation fluorescence microscopy of 
erythrocytes and erythrocyte ghosts 
 
Imaging of erythrocytes and empty erythrocyte ghosts was performed at 730 nm excitation 
wavelength using the home-made two-photon experimental set up developed by Rabasovic et al. 
(Rabasovic et al., 2015).  
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The excitation wavelength is of the great importance in this study and it has to be carefully  
selected according to its availability and the properties of the samples. Selection of the 
wavelength can significantly affect the chemical selectivity of the imaging, providing excitation 
of the specific and desired objects, and quality of the images by means of excitation efficiency 1 
and fluorescence strength. The excitation wavelength in this study is selected to be 730 nm by 
the following criteria:  
- Different excitation wavelengths within Ti:Sapphire laser tuning range  (700-1000nm) were 
tested. Obtained excitation spectrum is consistent with spectrum shown in study of Zheng et al., 
i.e. the excitation is the most efficient for the shortest wavelengths (Zheng et al., 2010).   
- The two photon excitation signal from hemoglobin at 650 nm excitation wavelength is reported 
to be more  efficient but we were not able to utilize shorter wavelengths than 700 nm due to laser 
tuning range (700-1000nm). Also, there is a significant leakage of the laser light to the PMT for 
wavelengths shorter than 730 nm. The cut-off wavelength of the dichroic mirror (hot mirror 
M254H45, Throlabs, Inc) is (700±10) nm with transmission >97% for wavelengths longer than 
710 nm, whereas full width at half maximum of the laser line is approximately 12 nm.   
- The two photon excitation signal from glass (coverslips and microscope slides) is pronounced 
for wavelengths shorter than 730 nm. Thus, 730 nm is the shortest possible choice for the 
excitation wavelength to produce still high quality images.  
 
Erythrocytes (hematocrit 5% i.e. 15 5% suspension) and ghosts in amount of 20 μL were allowed 
to settle onto a microscopic slide and covered by coverslips. 
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RESULTS AND DISCUSSION 
 
1. Controlled drug delivery system based on mesoporous 
silica 
1.1. Preclinical trial in beagle dogs 
In this study, two OMS formulations - Formac capsules, with different content of fenofibrate 
(33.5 and 16.75 mg) were compared with two referent systems Lypanthil® and Tricor® in terms 
of in vitro release and systemic exposure of fenofibrate and its metabolite when administered 
orally to dogs. The release profiles of the examined concepts are presented in Figure 7. The 
amount released of fenofibrate from the nanosized product Tricor® was 7.50 mg after 5 min. 
After 15 min, a steady-state was reached and lasted to the end of the experiment. The microsized 
product Lipanthyl® showed initial burst release with only 0.40 mg released after 5 minutes, 
reflecting very low solubility of the drug. It reached its maximum release after 120 min. On the 
other hand, OMS capsule containing the same amount of fenofibrate (33.5 mg), had higher initial 
burst release (0.72 mg after 5 min). The progress of the OMS capsule (eq. 16.75 mg) followed 
OMS capsule (eq. 33.5 mg) but with approximately twofold lower concentrations at each time 
point. At the end of the experiment the amount of fenofibrate released from Lipanthyl® and 
Tricor® was approximately 30 % from the initial dose. Both OMS capsules containing 33.5 and 
16.75 mg of fenofibrate attained a relatively high release of 66 and 60 % of their dose, 
respectively. These data clearly illustrate that the slow dissolution kinetics and low water 
solubility of fenofibrate from the marketed products could be overcome by loading it into OMS. 
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Figure 7. Dissolution/release experiments of Lipanthyl®, Tricor® and two OMS capsules in 900 
mL 0.1 N HCl + 0.1 % Tween 80: (A) released amounts in milligrams and (B) percent of the 
original form released. Results are mean ± SD of three experiments. 
Beagle dogs were selected to examine whether the fast in vitro release kinetics can be translated 
into an increased bioavailability of the drug. The animals were dosed orally with fenofibrate at a 
dose level of 33.5 (Lipanthyl®), 16.75 (OMS based formulation), 33.5 (OMS based formulation) 
and 48 (Tricor®) mg/animal in respectively period 1, 2, 3 and 4 (Table 2). During the study 
period no mortality occurred. Body weight of the beagle dogs was not significantly changed. 
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There were no clinical signs noted during the observation period. Single doses of Fenofibrate-
OMS were safe and well tolerated. No relevant differences in safety and tolerability profile were 
observed when comparing a single dose of Fenofibrate-OMS with Lipanthyl® and Tricor®. 
Figure 8 shows the average plasma concentrations versus time curves of fenofibrate and the 
active metabolite fenofibric acid after dosing. Low concentrations of fenofibrate were measured 
in plasma, with several peaks. Statistical analysis on the rate and extent of absorption were 
performed on the dose-normalised data. This dose-normalisation was justifiable due to the 
demonstrated dose proportionality in the present study between a 16.5 mg and 33.5 mg 
fenofibrate following oral administration. The mean systemic exposure for fenofibrate expressed 
as dose normalized AUClast was 0.04, 0.39, 1.03 and 0.88 h*ng/mL for the consecutive periods 
after oral dosing of fenofibrate. Mean dose normalized Cmax was respectively 0.056, 0.399, 0.249 
and 0.477 ng/mL for period 1 to 4. The mean systematic exposure for fenofibric acid expressed 
as dose normalized AUClast was 736, 2440, 2780 and 2750 h*ng/mL for the consecutive periods 
after oral dosing of fenofibrate. After oral dosing tmax was fast, varying between 0.5 and 2.0 hours 
after dosing. Mean dose normalized Cmax was respectively 145, 623, 524 and 562 ng/mL for 
period 1 to 4. After oral dosing of fenofibrate the interindividual variation in the PK parameters, 
as evaluated by % CV, was low to moderate: 38-67%, 25-31%, 31-62% and 10-43% for 
respectively period 1 to 4. 
Table 8. Plasma concentrations of fenofibrate and fenofibric acid of the different concepts. 
  Lipanthyl® OMS capsule 
16.75 mg 
OMS capsule 
33.5 mg 
Tricor® 
Fenofibrate pharmacokinetic data 
Dose level mg/kg 2.96 ± 0.119 1.48 ± 0.064 2.97 ± 0.105 4.28 ± 0.131 
t last h 1.5 - 2.0a 1.5 - 6.0a 4.0 - 12.0a 4.0 – 12.0a 
t max h 1.0 – 2.0a 1.0 – 1.5a 1.0 – 8.0a 0.5 – 4.0a 
C max ng/mL 0.163 ± 0.092 0.591 ± 0.393 0.733 ± 0.476 1.99 ± 2.69 
C maxb (kg ng)/(mL mg) 0.056 ± 0.033 0.399 ± 0.242 0.249 ±0.162 0.477 ± 0.65 
C last ng/mL 0.098 ± 0.099 0.048 ± 0.024 0.111 ± 0.104 0.048 ± 0.019 
AUC last h ng/mL 0.117 ± 0.065 0.58 ± 0.38 3.0 ± 2.52 3.70 ± 3.66 
AUC last b h kg ng/mL/mg 0.04 ± 0.023 0.39±0.26 1.03 ± 0.873 0.88 ± 0.883 
  Fenofibric acid pharmacokinetic data 
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Dose level mg/kg 2.96 ± 0.119 1.48 ± 0.064 2.97 ± 0.105 4.28 ± 0.131 
t last h 12 – 24a 24.0 24.0 24.0 
t max h 1.0 – 1.5a 0.5 – 1.5a 1.0 – 1.5a 0.5 – 2.0a 
C max ng/mL 433 ± 169 922 ± 283 1560 ± 892 2410 ± 1030 
C maxb (kg ng)/(mL mg) 145 ± 54.6 623 ± 190 524 ± 294 562 ± 233 
C last ng/mL 86.7 ± 107 64 ± 25 154 ± 74.3 233 ± 152 
AUC last h ng/mL 2200 ± 1460 3600 ± 905 8210 ± 2490 11 800 ± 1170 
AUC last b 
AUC∞ 
AUC∞b 
t1/2 
h kg ng/mL/mg 
h ng/mL 
h kg ng/mL/kg 
h 
736 ± 482 
1550* 
512* 
10.9* 
2440±629 
5190* 
3450* 
14.1* 
2780 ± 854 
13000* 
4440* 
18.2* 
2750 ± 278 
13400 
3110* 
8.71* 
a Range 
b Dose normalized to 1 mg/kg 
*Approximation 
As it may be observed from the presented data, the total exposure to fenofibrate and fenofibric 
acid, expressed as AUClast values, between the four different compounds was comparable 
between fenofibrate loaded OMS capsules (16.75 and 33.5 mg) and Tricor® (period 2, 3 and 4) 
and was approximately a factor 3.5 higher in comparison with Lipanthyl® (period 1). The extent 
of absorption expressed as the dose normalized AUClast was higher for fenofibrate-OMS (eq 33.5 
mg) than for the marketed formulations Lipanthyl® and Tricor®. Though some variability of 
the in vivo data, fenofibrate-OMS formulations show potential to improve bioavailability of 
fenofibrate. Consequently, the fenofibrate-OMS formulation (eq. 33.5 mg) whose 
pharmacokinetic profile of fenofibrate and its active metabolite fenofibric acid is confirmed 
(Figure 8A and 8B), with proven safety and satisfying tolerability, is a promising candidate to be 
further investigated in a clinical trial setting. 
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Figure 8. (A) Average plasma concentration versus time curves of fenofibrate after single dosing 
in male Beagle dog. (B) Average plasma concentration versus time curves of fenofibric acid after 
metabolization of fenofibrate. (The concentrations are normalized to 33.5 mg). Results are mean 
± SD obtained from four animals. 
Figure 9, which represents the release rate during stability testing (all conditions, 1, 2 and 6 
month time points), shows that the release profiles of OMS based formulation remained 
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unchanged in all the examined conditions within 6 months. Results from the DSC measurements 
showed absence of any crystallinity during the whole stability period. These results, that support 
the unique stability properties of the silica technology, are in accordance with the previously 
reported findings regarding ezetimibe-loaded OMS (Kiekens et al., 2011). 
 
Figure 9. Dissolution/release experiments of stability samples of ordered mesoporous silica 
(OMS) powder (n = 3; eq. 33.5 mg fenofibrate) in 900 mL simulated gastric fluid + Tween 80. 
Results are mean ± SD of three experiments. 
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1.2. Clinical trial 
In this study, the pharmaceutical performance of fenofibrate formulated with an ordered 
mesoporous silica material (Fenofibrate-OMS) was compared against the marketed product 
Lipanthyl®. Twelve healthy volunteers received a 33.5 mg dose of Fenofibrate-OMS and 67 mg 
of Lipanthyl® in two sequential dosing periods. Plasma concentrations of fenofibric acid, the 
pharmacologically active metabolite of fenofibrate, were monitored up to 96 hours post-dose. All 
subjects received the study drug as planned and all subjects completed the study as planned. 
Statistical analyses on the measures of the rate and extent of absorption were performed on the 
dose-normalised data. This dose-normalisation is justifiable based on the results of prior study 
that demonstrated dose proportionality between a 16.5 mg and a 33 mg fenofibrate dose 
following oral administration of Fenofibrate-OMS to fasted beagle dogs (Bukara et al., 2016).    
In the second administration period of the study, a quantifiable pre-dose plasma concentration 
was found in 4 subjects. In each case, the pre-dose plasma concentration was lower than 5% of 
the corresponding Cmax. In accordance with the regulatory guidelines, these data were used as 
such in the pharmacokinetic analysis. Since the lower limit of quantification (LLOQ) for plasma 
pharmacokinetic analysis was set at 10.0 ng/mL, all analytical values below this value were 
entered in the database ‘<10 ng/mL’. For each plasma sample, the difference between the actual 
sampling time and the scheduled sampling time was lower than 20%. 
The plasma concentration vs time profiles of fenofibric acid after administration of Fenofibrate-
OMS and Lipanthyl® are presented in Figure 10.  
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Figure 10. (A) Mean (n = 12) plasma concentration vs time profiles after single administration 
of one capsule containing 33.5 mg of fenofibrate formulated with OMS (Fenofibrate-OMS) or 
one capsule containing 67 mg of micronized fenofibrate (Lipanthyl®); (B) The same data after 
normalization to 1 mg dose. 
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An overview of all pharmacokinetic parameters is provided in Table 9 and a statistical 
comparison of the pharmacokinetic parameters is presented in Table 10.  
Table 9. Fenofibric Acid Pharmacokinetic Parameters. All data (except tmax data) are presented as 
mean ± standard deviation calculated from the 12 subjects having completed the two treatment 
periods. For tmax, median values are provided with the range presented in brackets. 
Pharmacokinetic Parameter Fenofibrate-OMS Lipanthyl® 
Cmax (µg/mL) 1.67 ± 0.29 1.96 ± 0.65 
tmax (h) 3.50 (2.00-5.00) 4.00 (2.00-6.00) 
AUC0-t (µg.h/mL) 30.8 ± 13.4 47.9 ± 22.0 
AUC0-24h (µg.h/mL) 18.7 ± 4.7 24.9 ± 8.6 
AUC0-48h (µg.h/mL) 26.3 ± 9.1 37.8 ± 14.7 
AUC0-∞ (µg.h/mL) 32.3 ± 14.7 51.9 ± 26.0 
t1/2,λz (h) 17.0 ± 6.2 22.1 ± 8.8 
Cmax/dose (µg/mL/mg) 0.0498 ± 0.0087 0.0293 ± 0.0097 
AUC0-t/dose (µg.h/mL/mg) 0.921 ± 0.401 0.715 ± 0.329 
AUC0-24h/dose (µg.h/mL/mg) 0.559 ± 0.140 0.372 ± 0.128 
AUC0-48h/dose (µg.h/mL/mg) 0.784 ± 0.272 0.565 ± 0.220 
Fenofibrate-OMS treatment: single oral dose of 33.5 mg fenofibrate formulated with ordered mesoporous 
silica; Lipanthyl® treatment: single oral dose of 67 mg micronized fenofibrate.  
Cmax = maximum observed plasma concentration;  
Cmax/dose = Cmax normalized to unit dose (1 mg);  
tmax = time of occurrence of Cmax;  
AUC = area under the plasma concentration versus time curve from time zero to the last sampling time at 
which concentrations were at or above the limit of quantification [AUC0-t], up to 24 hours post-dose 
[AUC0-24h], or up to 48 hours post-dose [AUC0-48h] calculated by the linear trapezoidal rule;  
AUC0-t/dose = AUC0-t normalized to unit dose (1 mg); AUC0-24h/dose = AUC0-24h normalized to unit dose 
(1 mg); AUC0-48h/dose = AUC0-48h normalized to unit dose (1 mg); AUC0- = Area under the plasma 
concentration versus time curve from time zero to infinity, calculated from AUC0-t + (Ct/z), where Ct is 
the last observed quantifiable concentration; AUC0-/dose = AUC0- normalized to unit dose (1 mg);  
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λz = apparent terminal elimination rate constant; t1/2,λz = apparent terminal elimination half-life, calculated 
from (ln 2)/z 
 
Table 10. Statistical Comparison of Fenofibric Acid Pharmacokinetic Parameters Between: 
Fenofibrate-OMS vs Lipanthyl®. 
Pharmacokinetic Parameter 
Fenofibrate-OMS vs Lipanthyl® 
Point estimate (90% CI)a p-valueb 
Cmax/dose 177.1 (152.5 – 205.8) < 0.0001 
tmax -0.75 (-1.25 – -0.25) 0.0344 
AUC0-t/dose 129.9 (120.5 –140.0) < 0.0001 
AUC0-24h/dose 154.1 (136.8 – 173.5) < 0.0001 
AUC0-48h/dose 140.5 (128.3 – 153.8) < 0.0001 
AUC0-∞/dose 127.0 (118.0 – 136.6) 0.0002 
t1/2,λz 77.6 (70.0 – 86.0) 0.0012 
Fenofibrate-OMS treatment: single oral dose of 33.5 mg fenofibrate formulated with ordered mesoporous 
silica; Lipanthyl® treatment: single oral dose of 67 mg micronized fenofibrate. 
aPoint estimate and 90% CI of the least-squares geometric percentage ratio (ANOVA).  
For tmax, comparison was assessed between Fenofibrate-OMS and Lipanthyl® using the Koch procedure;  
the Hodges-Lehmann non-parametric estimate of location shift between Fenofibrate-OMS and  
Lipanthyl® based on untransformed data is provided with its 90% two sided CI. 
bProbability of no difference between treatments (ANOVA; non-parametric test for tmax). 
 
Statistical comparison of the dose-normalised measures of extent of exposure (Table 10) reveals 
significantly higher values for Fenofibrate-OMS, with point estimates of 129.9%, 154.1%, 
140.5% and 126.7% for AUC0-t/dose, AUC0-24h/dose, AUC0-48h/dose and AUC0-∞/dose, 
respectively. The data in Table 10 also show a significant increase in Cmax/dose (point estimate 
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of 177%), a reduction in tmax (-0.75 hours) and a modest yet significant decrease in apparent 
terminal half-life (t1/2,λz) following administration of Fenofibrate-OMS.  
No serious adverse events occurred during this study and none of the subjects prematurely 
discontinued the study due to an adverse event. In total, 6 treatment-emergent adverse events 
were reported in 3 subjects (25.0%): 2 subjects (16.7%) in the period following administration of 
Fenofibrate-OMS and in 1 (8.3%) in the period following administration of Lipanthyl®. All 
treatment-emergent adverse events were mild in severity and were seen in at most one subject 
(nausea and back pain in one subject each and contusion, head injury, nail injury, and spinal cord 
injury cervical in one subject). One event was considered by the investigator to have a reasonable 
possibility of causal relationship with the study drug (nausea in the period following 
administration of Fenofibrate-OMS). No relevant differences in clinical laboratory test data were 
observed between Fenofibrate-OMS and Lipanthyl® and no clinically relevant changes from 
baseline in median values of any ECG parameter or vital signs were observed following 
administration of the study drug. No abnormalities were noted in any of the subjects during 
physical examination. 
Overall, the pharmacokinetic data revealed a significant increase in the extent of absorption 
following administration of Fenofibrate-OMS. The extent of absorption expressed as the dose-
normalised AUC from time zero to the 24 hour (AUC0-24h/dose) of 48 hour (AUC0-48h/dose) was 
significantly higher for Fenofibrate-OMS, with point estimates of ca 154% and 140%, 
respectively (Table 3), indicating an increase in systemic exposure of around 54% and 40%, 
respectively. These differences are significant within the 90% CI, which is above the minimum 
acceptance interval currently required by the European Medicines Agency (EMA) to conclude to 
bioequivalence (80-125%). Fenofibric acid exposure assessed until the last measurable 
concentration (AUC0-t/dose) or extrapolated to infinity (AUC0-∞/dose) was statistically 
significantly increased but to a lesser extent (30% and 27%, respectively) and with 90% CIs 
overlapping with the upper limit of the acceptance interval (80-125%) required to conclude to 
bioequivalence. 
The data also indicated an increased rate of absorption for Fenofibrate-OMS: the dose-
normalised maximum fenofibric acid plasma concentration (Cmax/dose) was increased by 77% (p 
< 0.0001) and the time to reach the maximum plasma concentration (tmax) was reduced by 0.75 
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hours (p < 0.05). The increased rate and extent of absorption following administration of 
Fenofibrate-OMS can be related to the release rate of fenofibrate from OMS which is faster than 
the dissolution rate of micronized fenofibrate (Lipanthyl®), thus providing for a higher driving 
force for drug absorption during gastrointestinal transit. These results, indicative of a higher 
pharmaceutical performance of Fenofibrate-OMS, are in line with those obtained previously in 
beagle dogs (Bukara et al., 2016). 
Single doses of Fenofibrate-OMS were safe and well tolerated. No relevant differences in safety 
and tolerability profile were observed when comparing a single dose of Fenofibrate-OMS and 
Lipanthyl®. 
 
2. Controlled drug delivery system based on erythrocyte 
membranes 
 
In this study, encapsulation of SD into porcine and outdated human erythrocyte ghosts was 
performed by osmosis based process, gradual hypotonic hemolysis. As previously shown (Kostic 
et al., 2014; Stojanovic et al., 2012) during the process of gradual decrease of osmotic strength 
of a solution surrounding erythrocytes, erythrocytes swell and hemoglobin molecules leak out. 
The transiently appeared membrane holes of 20–50 nm in the remaining erythrocyte membranes 
permit different extracellular substances to be encapsulated through these resealable pores (Fun 
et al., 2012). Beside already known phenomenon that different osmotic properties of the 
examined erythrocytes require the usage of different hypotonic conditions during encapsulation 
process, in this study the effect of the active substance - SD itself was examined on the 
encapsulation process, as well as on final properties of the encapsulated ghosts.  
In order to identify and quantify encapsulated SD in a complex systems such as erythrocyte 
ghost, we developed simple, fast and reliable UHPLC/DAD/–HESI-MS/MS method. The 
analysis included comparison of the retention times, UV and MS/MS spectra with the available 
standard. Initially, full-scan UHPLC/−HESI-MS spectrum of pure SD was acquired in negative 
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ion mode (Figure 1SB) simultaneously with UHPLC/DAD spectrum at =230 and 280 nm 
(Figure 11).  
 
 
Figure 11. UHPLC/−HESI-MS total ion chromatogram (TIC) of SD (A) and corresponding MS 
spectrum (B). UHPLC/DAD chromatogram of SD at =230 (C), and corresponding UV 
spectrum (D). 
Peak at Rt = 8.30 min corresponding to SD, showed characteristic deprotonated molecule m/z 
[M−H]− at 294, and max at 230 and 280 nm. The UHPLC/–HESI-MS/MS analysis, with cE set 
to 20 eV, revealed the major –MS2 product ions of SD: m/z [M−H−CO2]− at 250, m/z 
[M−H−CO2−Cl]− at 214 and m/z [M−H−CO2−2Cl]− at 178. UHPLC/–HESI-MS/MS PIS 
chromatogram and corresponding –MS2 spectrum is shown in Figure 12A1 and 12A2.  
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Figure 12. UHPLC/–HESI-MS/MS product ion scanning (PIS) chromatogram (A1) and 
corresponding spectrum of SD deprotonated molecule (m/z [M−H]− at 294) (A2). The proposed 
origin of mass fragments of SD is attached to the corresponding mass spectrum; UHPLC/–HESI-
MS/MS single reaction monitoring (SRM) chromatogram (A3) and corresponding mass 
spectrum (A4) presenting two characteristic –MS2 fragments used in experiments for the 
accurate identification and quantification of SD; (B) UHPLC/–HESI-MS/MS single reaction 
monitoring (SRM) chromatograms of human and porcine ghosts, and corresponding mass 
spectrums of diclofenac identified in samples. 
Proposed fragmentation pattern in negative ion mode is also presented. Two characteristic –MS2 
fragments, m/z at 250 and m/z at 214, were used in SRM experiment for the accurate 
identification and quantification of SD (Figure 12A3 and 12A4) in human and porcine ghosts 
(Figure 12B). Developed UHPLC/DAD/–HESI-MS/MS method allowing simple, precise and 
accurate determination and quantification of the SD encapsulated in erythrocyte ghost 
demonstrated its ability to be used as analytical method in potential biomedical/clinical use of 
these SD carriers. 
The amount of the encapsulated SD in 100 µL of erythrocyte ghosts was 21.5 µg and 4.85 µg for 
porcine and outdated human samples, respectively. It corresponds to the encapsulation efficiency 
of 37% for porcine and 8.5% for outdated human erythrocyte ghosts. After the second washing 
out step during the encapsulation procedure (performed to remove all un-encapsulated drug), the 
detected amount of SD in the supernatant was 1.15 % and 75.5 % of the encapsulated amount for 
porcine and outdated human erythrocyte ghosts, respectively. The encapsulation efficiency for 
porcine erythrocyte ghosts under the applied conditions was consistent with the range reported in 
other studies where erythrocyte ghosts were used to encapsulate various agents such as drugs, 
enzymes, peptides, proteins, pollysacharides and DNA (Hamidi et al., 2001; Millan et al., 
2004). Co-encapsulation methods or enriched medium which could be a source of nutrients for 
erythrocyte (such as Hank’s balanced salt solution) were not used in this study, so encapsulation 
efficiency was only the result of intrinsic ability of erythrocytes’ membranes to entrap the 
substance. On the other hand, the encapsulation efficiency for outdated human erythrocyte ghosts 
was much lower than the reported range for fresh human erythrocytes (Hamidi et al., 2001; 
Millan et al., 2004). This finding might be explained by the aging process and consequent 
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deterioration of erythrocytes during the storage. During aging/storage erythrocytes lose water, 
ATP, hemoglobin, proteins, surface N-acetylneuraminic acid and undergo age-related changes in 
band 3 (Huang et al., 2011). All these changes together and especially changes in band 3 which 
participate in hypotonic hemolysis process (Orhan et al., 2001) were probably responsible for 
the decreased ability of outdated human erythrocytes to entrap the drug. 
It was noted that with the applied encapsulation process, SD loaded porcine erythrocyte ghosts 
retained more hemoglobin in comparison with the empty erythrocyte ghosts. UV/VIS 
spectrophotometric measurements confirmed this observation revealing that the concentration of 
the residual hemoglobin in some of SD loaded porcine erythrocyte ghosts was even 3-4 folds 
higher than in the suspension of corresponding empty erythrocyte ghosts. On the other hand, the 
level of residual hemoglobin in outdated human SD loaded and empty erythrocyte ghosts was 
almost equal (0.50% and 0.46% respectively). This was an incentive to investigate the effect of 
SD on the gradual hypotonic hemolysis process. 
As it is shown in Figure 13, during the gradual hypotonic hemolysis SD had only weak 
antihemolytic effect on porcine erythrocytes. H50 values (the point when 50% of total 
hemoglobin is released from erythrocytes) were 5.3±0.73 and 5.84±0.5 minutes for erythrocytes 
suspension lysed in the hypotonic buffer without and with SD, respectively, and they didn’t show 
statistically significant difference (p > 0.05). However during the washing out procedure as a part 
of encapsulation process, this effect became more pronounced and SD loaded porcine 
erythrocyte ghosts were losing hemoglobin slower than the corresponding empty ghosts. The 
difference in the hemoglobin content between SD loaded and empty erythrocyte ghosts became 
statistically significant after the fourth washing out step and amounted about 20% on average 
(Fig. 13C). 
It is known that SD exerts biphasic effect on hemolysis: it stabilizes membrane at lower 
concentrations while causing hemolysis at higher concentrations (Orhan et al., 2001). In this 
study SD was used in steady state therapeutic concentration (Orhan et al., 2001) which had very 
mild and delayed antihemolytic effect for porcine erythrocytes. Antihemolytic effect of 
amphyphiles is well known and extensively described in literature (Sato et al., 1993; Seeman, 
1972; Helenius et al., 1975; Sanchez et al., 2002). Currently, there are several hypothesis 
explaining this phenomenon but it requires further detailed studies (Sato et al., 1993; Seeman, 
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1972; Helenius et al., 1975; Sanchez et al., 2002). Regardless the mechanism involved, 
observed mild and delayed antihemolytic effect of SD did not affect encapsulation process 
adversely.  
It is interesting to note that in the present study SD didn’t show antihemolytic effect on the 
outdated human erythrocytes. These erythrocytes are known to have impaired signalling 
pathways (Bosman et al., 2008) which together with our finding supports the assumptions that 
some active mechanism is involved in antihemolytic effect of amphiphiles. 
Furthermore, the potassium concentration during the gradual hypotonic hemolysis of porcine 
erythrocytes was measured with and without presence of SD. As it may be observed from the 
Figure 1B slight increase in potassium efflux was detected in the presence of SD between 11th 
and 17th minute. However, the difference between the samples was not statistically significant (p 
> 0.05). Increased potassium efflux is the common effect shared by the most amphiphiles (Isoma 
et al., 1986). According to Isomaa et al. (Isoma et al., 1986) amphiphiles increase the 
permeability of the membrane lipid bilayer to the small ions, such as potassium, by decreasing 
order of packing of the hydrocarbon chains of the lipids in the bilayer.  
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Figure 13. Effect of SD on: (A) the gradual hypotonic hemolysis, (B) potassium efflux during 
the gradual hypotonic hemolysis (C) washing out procedure of porcine erythrocyte ghosts. 
Results are mean ± SD of three experiments. 
Number-based particle hydrodynamic diameter distribution curves and statistical measures of the 
porcine and outdated human erythrocytes, erythrocyte ghosts and erythrocyte ghosts loaded with 
SD are shown in Figure 14. The results confirmed that porcine erythrocytes were smaller than 
human erythrocytes. Porcine ghosts with and without SD were also smaller than the 
corresponding outdated human samples. It is obvious from the statistical data that the empty 
ghosts and ghosts loaded with SD were unidispersed introducing important property for their 
potential application as drug carriers. After the gradual hypotonic hemolysis process and 
washing out procedure, porcine empty erythrocyte ghosts were on average about 13% smaller 
that the intact erythrocytes. On the contrary, outdated human empty erythrocyte ghosts showed 
an increase in size for about 10% in comparison with erythrocytes. Subsequently applied 
encapsulation process caused an increase in ghosts’ size of both examined species. Porcine 
erythrocyte ghosts loaded with SD were about 9% larger than the empty ghosts but still smaller 
than starting erythrocytes. Outdated human erythrocyte ghosts loaded with SD were 
approximately 14 % larger than empty ghosts and larger than starting erythrocytes. 
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Figure 14. Number based hydrodynamic diameter distribution and relevant statistical parameters 
of (A1) porcine erythrocytes, (A2) porcine erythrocyte ghosts, (A3) porcine erythrocyte ghosts 
loaded with SD, (B1) outdated human erythrocytes, (B2) outdated human erythrocyte ghosts 
(B3) outdated human erythrocyte ghosts loaded with SD. (p > 0.05 when intact erythrocytes and 
empty erythrocyte ghosts were compared and when empty erythrocyte ghosts and SD loaded 
erythrocyte ghosts were compared). 
The decrease in erythrocytes’ size in gradual hypotonic hemolysis process has been previously 
reported for porcine erythrocytes (Kostic et al., 2014). Montes et al. (Montes et al., 2008) 
showed threefold smaller human erythrocyte ghosts than the original cells using isolation by 
classical hemolysis, i.e. osmotic shock. In the present study where an increase in the size of the 
ghosts was detected, outdated human erythrocytes obviously lost ability to shrink. On the other 
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hand, porcine erythrocyte ghosts retained size smaller than the original cells. Surface active 
drugs as well as non-steroidal anti-inflammatory compounds are reported to self-associate and 
bind to membranes causing the disruption and solubilisation as in detergent-like way (Lopes et 
al., 2004). Lopes and co-workers showed that SD associates with the lipid bilayer of liposome 
causing its destruction and the decrease in size (Lopes et al., 2004). This phenomenon was not 
observed in our study. Erythrocyte ghosts which contain spectrin - actin network (membrane 
skeleton) in addition to the lipid bilayer (Bennett et al., 1979), seem to be resistant to SD’s 
surface active property offering the advantage in comparison with liposomes. 
Possible interactions between SD and erythrocyte ghosts as well as changes induced by the 
applied encapsulation process were investigated by FT-IR (Figure 15). 
The spectra of SD had been described by Bouchal et al. (Bouchal et al., 2016). In the high 
frequencies range signals due to N-H stretching were found at 3382 and 3258 cm-1 (Fig. 15). 
Signals due to C-H stretching in the aliphatic and aromatic part of molecule were found in 3100-
2850 cm-1 range (Bouchal et al., 2016). Peaks at 1572 and 1401 cm-1 belong to asymmetric and 
symmetric stretching modes of carboxylate group, respectively (Bouchal et al., 2016). Signals in 
1603–1586 cm-1 range are the consequence of NH deformation modes and ring stretching modes 
(Bouchal et al., 2016). Lower frequency range consists of C–N stretching modes (1300–1200 
cm-1), in plane (1200–1000 cm-1) and out of plane (900–690 cm-1) CH deformations (Bouchal et 
al., 2016). 
The analysis of IR spectra of porcine and human erythrocyte ghosts not loaded with SD (Fig. 15) 
revealed the presence of amide I region predominantly containing α-helix structure at 1656 cm-1 
and amide II region at 1543 cm-1 (Dong et al., 1994). The relative intensity decrease of amide II 
band compared to amide I in the case of outdated human erythrocyte ghosts loaded with SD 
indicates change in the tertiary structure evoked by the presence of SD. 
According to Casal and Mantsch phospholipid infrared bands in the spectrum can be divided into 
three different regions corresponding to the hydrophobic, interfacial and polar moieties of the 
lipid (Casal et al., 1984). C-H stretching vibrations give rise to bands in the hydrophobic 3100–
2800 cm-1 region (Mantsch et al., 1991). As it may be observed from the Figure 15, asymmetric 
and symmetric CH2 bands at 2926 and 2852 cm
-1, respectively, which are the strongest ones in a 
phospholipid spectrum (Mantsch et al., 1991) are clearly observable in porcine and human 
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erythrocyte ghosts, as well as in their SD loaded forms. Shifting of the symmetric CH2 band 
toward higher frequencies that is according to Szalontai et al. (Szalontai et al., 2002) attributed 
to the ‘structural’ disorder imposed on the lipids was not detected after the applied encapsulation 
process. The most prominent band arising from the interfacial region is due to stretching 
vibrations of the carbonyl group involved in ester bonds and it is found at 1730 cm-1 and 1737 
cm-1 for porcine and human ghosts, respectively (Mantsch et al., 1991). This band that is very 
responsive to changes in its environment (Mantsch et al., 1991), is found at the same positions in 
the corresponding SD loaded porcine and human ghosts. 
The antisymmetric PO2
- stretching mode (Mantsch et al., 1991) appeared at 1245 cm-1 in both 
porcine and human empty and SD loaded ghosts. The symmetric PO2
- stretching mode (Mantsch 
et al., 1991) appeared at 1085 cm-1 in human ghosts and was slightly shifted to 1093 cm-1 after 
the applied encapsulation process (signed with asterisk). Also, this mode was observed at 1121 
cm-1 in porcine ghosts but was shifted to 1092 cm-1 in SD loaded ghosts (signed with asterisk). 
The band shift observed for the symmetric PO2
- stretching bands suggest that the SD might be 
located close to the phosphate moiety of lipid molecules. This finding is in agreement with the 
study which has previously shown that SD has a potential to interact with phosphate of 
phosphatidylcholine head groups in liposomes (Lopez et al., 2004). Comparing the spectra of 
porcine and human empty erythrocyte ghosts with ghosts loaded with SD, no new absorption 
peaks appeared. 
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Figure 15. FTIR spectra of sodium diclofenac (SD), human erythrocyte ghosts, human 
erythrocyte ghosts loaded with SD, porcine erythrocyte ghosts, porcine erythrocyte ghosts loaded 
with SD. (Asterisk - a band corresponding to the symmetric PO2
- stretching mode). 
Table 11 shows the values of zeta (ζ)-potential and conductivity (σ) of the examined porcine and 
human erythrocyte samples. As it may be observed, gradual hypotonic hemolysis and 
encapsulation process didn’t affect significantly surface charge and conductivity of the starting 
porcine erythrocyte suspension. The maintenance of this feature is important for two reasons: (1) 
when the expression of sialic acid in the erythrocyte surface is reduced, the electrostatic 
repulsive force decreases and erythrocyte aggregation is accelerated (Shiga et al., 1990), (2) 
negatively charged cells represent a good template core for layer by layer coating (Shaillender et 
al., 2011). Statistically significant difference in ζ-potential between human erythrocytes and 
erythrocyte ghosts (p < 0.05) indicates increased loss of N-acetylneuraminic acid probably 
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caused with an aging process potentiated in the seven week storage conditions (Huang et al., 
2011). A slight decrease in the surface charge of both porcine and outdated human SD loaded 
erythrocyte ghosts in comparison with the corresponding empty ghosts and intact erythrocytes 
might be a contribution of the negatively charged SD attached to the membrane surface. 
Table 11. Values of zeta (ζ)-potential and conductivity (σ) for porcine and human erythrocyte 
samples. 
Sample ζ-potential (mV) σ (mS/cm) 
Porcine erythrocytes                                                                    -9.4±0.61 15.9±0.66 
Porcine erythrocyte ghosts -9.6±0.70 15.6±0.66 
Porcine erythrocyte ghosts loaded with SD -10.1±0.12 15.7±0.50 
Human erythrocytes -12.5±0.89 15.7±0.58 
Human erythrocyte ghosts -11.7±0.59a 15.6±0.47 
Human erythrocyte ghosts loaded with SD -13.0±0.43 15.8±0.47 
aSignificant difference in ζ-potential value of the human erythrocytes. 
Zhbanov et al. (Zhbanov et al., 2015) showed the increase of blood conductivity due to 
aggregation of erythrocytes both theoretically and experimentally. Since changes regarding 
conductivity were not detected, this result might be a confirmation for the low aggregation 
ability of the SD loaded ghosts in the final formulation. 
Atomic force microscopy revealed significant difference between isolated porcine and outdated 
human erythrocytes’ morphology (Figure 16A1, 16B1). As it may be observed, starting porcine 
erythrocytes had echynocytic morphology (Fig. 16A1), contrary to the biconcave morphology of 
outdated human erythrocytes (Fig. 16B1). Gradual hypotonic hemolysis induced significant 
distortion in erythrocyte shape and altered surface texture in both species. Additionally, 
nanoscale alterations and damages were noted in empty erythrocyte ghosts originating from 
outdated human erythrocytes. Surface roughness values for empty porcine and outdated human 
erythrocyte ghosts amounted 37±3 nm and 7±2nm, respectively. After the applied encapsulation 
process Rrms surface roughness value did not change significantly for porcine sample and it 
amounted 33±9 nm. On the other hand, Rrms surface roughness value of SD loaded outdated 
human erythrocyte ghosts increased to 23±4 nm. Since erythrocytes are not flat surfaces and 
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curvature effect might affect surface roughness values, they were not compared with empty and 
SD loaded ghosts. 
 
Figure 16. Representative AFM images and corresponding width/height plots for (A) porcine 
samples: (1, 2) erythrocytes, (3, 4) erythrocyte ghosts, (5, 6) erythrocyte ghosts loaded with SD 
and (B) human samples: (1, 2) erythrocytes, (3, 4) erythrocyte ghosts, (5, 6) erythrocyte ghosts 
loaded with SD. 
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The echynocyte morphology of porcine erythrocytes represents a common artefact in handling of 
porcine blood (Barger, 2010). Even though it was expected that outdated human erythrocytes 
would also have echinocyte morphology due to in vitro aging during the storage (Girasole et al., 
2010), they had “normal” shape of flattened biconcave disc. The observed nanoscale damages on 
the outdated human erythrocyte ghosts indicated their impaired membrane-skeleton integrity and 
higher sensitivity in comparison with the fresh porcine erythrocytes. The damages of the 
outdated human erythrocytes might be one of the reasons for relatively high level of SD leakage 
during the washing out procedure and low level of SD encapsulation. Erythrocyte membrane 
roughness is a morphological parameter that links together the development of nanoscale 
alterations on the cell membrane with an occurrence of membrane-skeleton defects (Girasole et 
al., 2010). In the case of porcine erythrocyte ghosts, crosslinking of spectrin with glutaraldehyde 
during the encapsulation process (Shiga et al., 1990) seems to ‘improve’ surface properties 
making the membrane smoother. On the other hand SD loaded outdated human erythrocyte 
ghosts had higher Rrms values in comparison with the corresponding empty membranes which 
indicates further rearrangement and perturbations of the surface induced by the encapsulation 
process. During storage the most central biochemical change is a decrease in ATP which is 
important in the maintenance of membrane structure and integrity (Bosman et al., 2008). Due to 
its loss, erythrocytes become effete (Bosman et al., 2008), so higher susceptibility of the 
outdated human samples to the surface roughness changes was not surprising. 
Data given in Figure 17 show that SD loaded porcine and outdated human erythrocyte ghosts had 
different drug releasing profiles. Porcine erythrocyte ghosts showed very slow initial release with 
only 8% of the drug released within the 2 hours, followed by 35% of the encapsulated SD 
released after 96 hours. On the other hand, outdated human erythrocyte ghosts initially released 
about two fold higher amount (~16%) of the encapsulated SD within 2 hours in comparison with 
porcine ghosts. The established steady-state of SD between human erythrocyte ghosts and the 
buffer solution used for the release test within 1 hour, has not changed significantly during the 
next 96 hours. 
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Figure 17. Release profile of SD from porcine and outdated human erythrocyte ghosts as a 
function of time. 
Porcine erythrocyte ghosts didn’t show undesirably high burst release which may lead to toxicity 
and wastage of an encapsulated agent (Shaillender et al., 2011). The amount of released drug 
within 2 hours from porcine ghosts was much lower in comparison with the other reported SD 
controlled drug delivery systems such as solid lipid nanoparticles (Liu et al., 2014), chitosan 
spheres (Liu et al., 2014), PLGA-nanoparticles (Liu et al., 2014) and rat erythrocyte ghosts 
(Kozakevych et al., 2013). In addition to the lower burst release, porcine ghosts had slower 
release rate in comparison with the previously mentioned systems. These findings indicate that 
the porcine erythrocyte membranes derived from the slaughterhouse blood are minimally porous 
and responded very well on the exposure to the resealing hypertonic solution which is intended 
to cause shrinkage during the encapsulation process. This is in accordance with the retained 
ability of porcine ghosts to shrink reflected through the smaller size of SD loaded ghosts in 
comparison with the starting erythrocytes. Membrane holes successfully closed along with cross-
linked membrane proteins with 0.01 % glutaraldehyde were suitable for achievement of slow and 
extended (prolonged) SD release profile where release rate was based on equilibrium of released 
and drug retained within ghosts. 
On the other hand, SD loaded human erythrocyte ghosts prepared from the outdated erythrocytes 
with impaired structure and function due to aging during the storage (Huang et al., 2011) 
showed entirely different SD release pattern from porcine ghosts. As it was shown in Figure 17, 
during the in vitro drug release testing, an increase in SD concentration was not detected with 
85 
 
time indicating zero-order drug release. SD which probably interacted with the membrane (but 
was not entrapped inside the membranes due to proven loss of ability to shrink) was released in 
the medium to the moment when the concentration equilibrium was established. This was in 
agreement with assumed mechanism of SD retaining in outdated human ghosts by FTIR analysis. 
According to Briones et al. who obtained similar drug releasing profile for zidovudine in rat 
erythrocytes, this type of behavior allows the system to work as a drug reservoir, providing 
sustained release into the body (Briones et al., 2010). 
After comparing encapsulation efficiency of fresh porcine erythrocytes obtained in this study 
with data on those of fresh human erythrocytes found in the scientific literature, we assumed that 
preserved structure and function of the membranes seem to be a prerequisite for their usage in 
encapsulation process. 
As it was previously mentioned, during the process of gradual decrease of ionic strength of the 
solution surrounding erythrocytes, they swell and hemoglobin molecules leak out, remaining 
intact erythrocyte membranes (Kostic et al., 2014; Danon, 1961). Preparation of ghosts is being 
followed by an extensive washing out procedure (to remove extracellular hemoglobin released 
from lysed erythrocytes). However, a small amount of hemoglobin, so called residual 
hemoglobin always remains bound to membranes in resulting erythrocyte ghosts (Kostic et al., 
2014). The fraction of this so called residual hemoglobin, which cannot be easily eliminated 
from the system, significantly affects subsequent encapsulation process and encapsulated drug 
releasing profile (Kostic et al., 2014). 
The overall presence of residual hemoglobin in the final suspensions of erythrocyte ghosts was  
primarily determined by cyanmethemoglobin assay (Figure 18). The concentration of residual 
hemoglobin was 7.21 and 1.76 g/L for porcine and human sample, respectively. This reflects the  
decrease in concentration of hemoglobin by 95% and 99% in the suspension of erythrocyte ghost  
comparing to the starting suspensions of porcine and outdated human erythrocytes, respectively. 
These amounts of residual hemoglobin in erythrocyte ghosts are consistent with the range  
reported in other studies (Bernestein et al., 1938; Danon et al., 1956). However, the localization 
of residual hemoglobin in the suspension still remains unknown. 
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Figure 18. Concentration of hemoglobin in erythrocytes and their ghosts obtained by gradual 
hemolysis. The concentration was determined by spectrophotometric cyanmethemoglobin 
method. 
 
Two photon excitation fluorescence microscopy as an advanced technique offers the possibility 
for non-invasive, label-free high resolution imaging of living cells and deep tissues by using the 
fluorescence emission from the endogenous fluorescent molecules (Masters et al., 2008). The 
near infrared radiation generates two photon excitation signals of endogenous fluorophores, such 
as tryptophan, riboflavines, nicotinamides, collagen, elastin etc., and thus provides rich 
morphological and biochemical information of biological systems (Kolesová et al., 2016; Wang 
et al., 2006). Less investigated and reported is intrinsic fluorescence of hemoglobin, the main 
intracellular component of erythrocytes, which emits strong Soret fluorescence with the peak at 
438 nm upon two-photon excitation by femtosecond pulses in red and near infrared region (600-
750 nm) (Zheng et al., 2010). Such optical properties of hemoglobin opened the possibility to 
use two photon excitation microscopy as a tool for label-free imaging of erythrocytes, even in 
vivo (Li et al., 2011). 
Besides spatial distribution of hemoglobin in intact human and porcine erythrocytes, images of 
residual hemoglobin in erythrocyte ghosts also can be obtained by two photon excitation 
fluorescence microscopy (Figures 19 and 20, respectively). Intensity of two photon excitation 
signal depends on the concentration of the hemoglobin, but also on the pulse peak power, pulse 
duration, repetition rate, focal volume, excitation wavelength etc. In order to evaluate the local 
87 
 
change (i.e. decrease) in hemoglobin content after the hemolysis, we mixed the ghosts with intact 
erythrocytes. In this way we can evaluate local content of hemoglobin, i.e. distribution of 
hemoglobin across erythrocytes and ghosts, and not only average value for whole cell or 
suspension. From the image data we obtained variation of intensity along appropriately chosen 
representative lines, as depicted in Figures 19 and 20. The line is chosen in the way to intercept 
at least two erythrocytes and two ghosts which provide up to 8 representative points positioned 
in the proximity of membrane within the cells for comparison of two photon excitation signals. 
Note that the signals from the chosen points provide highly localized data for the comparison, 
just opposite to the cyanmethemoglobin assay, which is intrinsically averaging method. This 
ensures the same excitation parameters for both, erythrocytes and erythrocyte ghosts. The above 
procedure ensures that the peak ratio from the two photon excitation intensity profile is equal to 
the concentration ratio in the untreated erythrocyte(s) and the ghost(s). We emphasize that this 
simple step enables us to determine changes in the content of residual hemoglobin in ghosts 
relative to the starting content of hemoglobin in intact erythrocytes, but not the absolute 
concentration. 
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Figure 19. Mixed suspension of human erythrocytes and resulting erythrocyte ghosts: (A) bright 
field microscopy image; (B) two photon excitation microscopy image; (C-G) two photon 
excitation signal profiles along the corresponding lines at (B) image. Profiles 3 and 4 are given in  
magnified vertical scale in (F) and (G) graphs. Black curves are raw data plot, red and green 
curves are obtained upon adjacent points averaging. 
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Figure 20. Mixed suspension of porcine erythrocytes and resulting erythrocyte ghosts: (a) bright 
field microscopy image; (B) two photon excitation microscopy image; (C-G) two photon 
excitation signal profiles along the corresponding lines at (B) image. Profiles 3 and 4 are given in  
magnified vertical scale in (F) and (G) graphs. Black curves are raw data plot, red and green 
curves are obtained upon adjacent points averaging. 
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As can be seen from the Figures 19 and 20, after the conversion of erythrocytes to empty 
erythrocyte membranes, fluorescence emission from hemoglobin significantly decreased, but 
was still detectable. Therefore, the applied process that we used allows the production of ghosts, 
however a certain amount of the hemoglobin always remains bound to the membrane. 
Comparing the peak values from graphs 19 (D) and (E) (red curves) to those in graphs 19 (F) and 
(G) one can estimate lower fluorescence emission for both porcine and human erythrocyte ghosts 
in comparison to respective erythrocytes. Our results suggest that residual hemoglobin in the 
suspension was localized on intracellular side of the ghost membranes. The two photon 
excitation signal in the internal volume of both, human and porcine erythrocyte ghosts is at the 
noise level, thus  hemoglobin content is negligible. 
These results supports already reported data on hemoglobin ability to bind to erythrocyte 
membrane via transmembrane protein, e.g. band 3 or some other cytoskeleton proteins via α   
globin chains (Murakami et al., 2003). This phenomenon that we have confirmed by two photon 
excitation microscopy could be used as valuable marker of inevitable oxidative damages 
(Sharma et al., 2001) emerged during in vitro storage and erythrocytes handling. The higher 
concentration of residual hemoglobin obtained in porcine ghosts relative to initial concentration, 
can be explained by specific membrane lipid composition and their high susceptibility to 
oxidative stress induced by reactive oxygen species (Brzezińska-Slebodzińska, 2003) related to 
lower level of enzymes protectants against oxidative damages (Vodela et al., 1997). 
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CONCLUSION 
 
According to results obtained during the examination of two controlled drug delivery systems 
based on ordered mesoporous silica and erythrocyte ghosts following conclusions can be 
withdrawn: 
- The ability of ordered mesoporous silica material (OMS) to improve biopharmaceutical 
performance of poorly soluble compound fenofibrate, was confirmed in vitro. In vivo 
study in dogs revealed pharmacokinetic profile of fenofibrate and its active metabolite 
fenofibric acid after oral administration of fenofibrate-OMS formulations. This study 
indicative of the potential of OMS-based formulations to improve bioavailability of 
fenofibrate, revealed good tolerability and satisfying safety level of the used dose (eq. 
33.5 mg) of fenofibrate in this highly stable formulation and opened the possibility for its 
further in vivo testing in humans. 
- The results of the clinical trial indicated that administration of an ordered mesoporous 
silica based formulation of fenofibrate resulted in an increased rate and extent of 
absorption in humans when compared to a marketed product. In addition, single doses of 
the ordered mesoporous silica based formulation were well tolerated by all volunteers. 
The present study is the first to demonstrate the bioavailability-enhancing potential of this 
novel formulation approach in man, and evidences the utility of this technique to 
overcome bioavailability problems associated with poor solubility. 
- Although SD due to its surface active properties may bind to membranes and cause its 
disruption and solubilisation as in detergent-like way, under the applied process based on 
gradual hemolysis it was successfully encapsulated in erythrocyte ghosts. Despite its 
antihemolytic effect at lower concentrations, relatively high encapsulation efficiency was 
achieved. Comparing the two inexpensive, widely available materials-slaughterhouse 
porcine and outdated transfusion human blood, we demonstrated more preserved 
structure and functional properties of porcine erythrocytes related to the superior 
encapsulation and release of SD, and defined them as more promising candidate for the 
usage in SD encapsulation process on a large scale. However, obtained results indicate 
the necessity of further investigation in order to produce universal effective SD carrier 
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based on erythrocyte ghosts. These approaches depending of the administration route will 
include layering with different polymers (in order to mask the antigen determinants on 
the surface and to control relase more subtle), as well as examination of their behaviour 
in vivo.  
The present study offers a potential solution for the problem of slaughterhouse waste 
disposal and on the other hand it contributes to the defining of the optimal formulation 
for diclofenac. 
- Two-photon excitation fluorescence (2PE) microscopy can be used in analysis of spatial 
distribution of hemoglobin in erythrocytes and erythrocyte ghosts, at individual cell level. 
High-quality, label- and fixation- free visualization of hemoglobin can be achieved at 
730nm excitation wavelength. The 2PE fluorescence signal from residual hemoglobin at 
representative points near the cell membrane in the ghosts was reported to have lower 
intensity than at the corresponding points in intact erythrocytes. Hemoglobin distribution 
in erythrocytes together with residual hemoglobin content and distribution in resulting 
erythrocyte ghosts can be directly and relatively easily estimated. The proposed method 
could be of significant importance for identifying different pathological or non-
pathological conditions and application in material selection in biotechnological 
processes. 
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